| nr |
titel |
auteur |
tijdschrift |
jaar |
jaarg. |
afl. |
pagina('s) |
type |
| 1 |
Author index
|
|
|
|
211 |
S1 |
p.
|
artikel
|
| 2 |
Contents
|
|
|
|
211 |
S1 |
p.
|
artikel
|
| 3 |
Copyright Page
|
|
|
|
211 |
S1 |
p.
|
artikel
|
| 4 |
Editorial Board
|
|
|
|
211 |
S1 |
p.
|
artikel
|
| 5 |
501LBA LBA Orals: Phase 1 expansion results of IDE397, a first-in-class, oral, MAT2A inhibitor (MAT2Ai) in MTAP deleted(del) non-small cell lung cancer (NSCLC) and urothelial cancer (UC)
|
Herzberg, B.
|
|
|
211 |
S1 |
p.
|
artikel
|
| 6 |
500LBA LBA Orals: Preliminary safety and anti-tumor activity of TYRA-300, a highly selective FGFR3 inhibitor, in participants with advanced solid tumors with activating FGFR3 mutations/fusions (SURF301)
|
Tran, B.
|
|
|
211 |
S1 |
p.
|
artikel
|
| 7 |
502LBA LBA Orals: Preliminary safety, pharmacokinetics, and antitumor activity of RMC-9805, an oral, RAS(ON) G12D-selective, tri-complex inhibitor in patients with KRAS G12D pancreatic ductal adenocarcinoma (PDAC) from a phase 1 study in advanced solid tumors
|
Hong, D.S.
|
|
|
211 |
S1 |
p.
|
artikel
|
| 8 |
503LBA LBA Orals: Results from CA240-0007, a phase 1/2 multiple expansion cohort study of BMS-986504 in patients (pts) with advanced solid tumors with homozygous MTAP deletion (MTAP-del)
|
Rodon, J.
|
|
|
211 |
S1 |
p.
|
artikel
|
| 9 |
506LBA (PB-506) LBA Posters: Ablation of Src Family Kinases FGR in hosts reduces confers response of high-grade ovarian cancer to immune checkpoint blockade treatment
|
Ernst, M.
|
|
|
211 |
S1 |
p.
|
artikel
|
| 10 |
509LBA (PB-509) LBA Posters: A novel PDE10 inhibitor targets cancer cells and MDSC to reverse the immunosuppressive tumor microenvironment: antitumor activity in multiple tumor types
|
Piazza, G.
|
|
|
211 |
S1 |
p.
|
artikel
|
| 11 |
513LBA (PB-513) LBA Posters: BCCA7693 - A novel, orally bioavailable DNA-PK inhibitor demonstrates efficacy with targeted MAPK and PARP therapeutics by slowing the development of acquired resistance
|
Kyle, A.
|
|
|
211 |
S1 |
p.
|
artikel
|
| 12 |
515LBA (PB-515) LBA Posters: CID-078, a first-in-class oral macrocycle cyclin A/B-RxL inhibitor, demonstrates anti-tumor activity in E2F-driven cancers
|
Evangelista, M.
|
|
|
211 |
S1 |
p.
|
artikel
|
| 13 |
517LBA (PB-517) LBA Posters: Computational prediction of survival post induction therapy for acute myeloid leukaemia
|
Giorni, A.
|
|
|
211 |
S1 |
p.
|
artikel
|
| 14 |
508LBA (PB-508) LBA Posters: Deferasirox’s anti-chemoresistance and anti-metastatic effect on nonsmall cell lung carcinoma
|
Delgado, Y.
|
|
|
211 |
S1 |
p.
|
artikel
|
| 15 |
510LBA (PB-510) LBA Posters: Dose-dependent cytotoxicity of arfolitixorin, a direct-acting folate, versus leucovorin with 5-fluorouracil in patient-derived colorectal cancer tumoroids (PDTs)
|
Bruun, J.
|
|
|
211 |
S1 |
p.
|
artikel
|
| 16 |
504LBA (PB-504) LBA Posters: Monitoring of endogenous target occupancy in cells and patient biopsies using FCCS
|
Becker, F.
|
|
|
211 |
S1 |
p.
|
artikel
|
| 17 |
512LBA (PB-512) LBA Posters: Off-the-Shelf Therapeutic Overactivation (TOA): A plea we can’t refuse!
|
Mazahreh, F.
|
|
|
211 |
S1 |
p.
|
artikel
|
| 18 |
516LBA (PB-516) LBA Posters: Potassium/sodium cation carriers robustly upregulate CD20 antigen by targeting MYC and synergize with anti-CD20 immunotherapies to eliminate malignant B cells
|
Pyrzynska, B.
|
|
|
211 |
S1 |
p.
|
artikel
|
| 19 |
520LBA (PB-520) LBA Posters: Preclinical characterization of LY4175408, a novel PTK7 targeting antibody-drug conjugate, utilizing exatecan via a hydrophilic polysarcosine linker platform
|
Sagar, D.
|
|
|
211 |
S1 |
p.
|
artikel
|
| 20 |
521LBA (PB-521) LBA Posters: Pre-targeting with in vivo Click Chemistry Enables Preferential Drug Exposure in Tumors versus Normal Tissues
|
Biechele, T.
|
|
|
211 |
S1 |
p.
|
artikel
|
| 21 |
511LBA (PB-511) LBA Posters: Selective Targeting of Cyclin E1 Using Molecular Glue Degraders in CCNE1 Amplified Solid Malignancies
|
Ilic-Widlund, N.
|
|
|
211 |
S1 |
p.
|
artikel
|
| 22 |
505LBA (PB-505) LBA Posters: Synthetic lethality of mRNA quality control complexes in cancer
|
Pappano, W.
|
|
|
211 |
S1 |
p.
|
artikel
|
| 23 |
519LBA (PB-519) LBA Posters: The novel pan-RAF-MEK glue NST-628 is highly efficacious as monotherapy and as an anchor for vertical inhibition of the RAS-MAPK pathway in KRAS-mutant cancers
|
Ryan, M.
|
|
|
211 |
S1 |
p.
|
artikel
|
| 24 |
514LBA (PB-514) LBA Posters: Updated safety and efficacy from a Phase 1 study of RMC-6236, a RAS (ON) multi-selective, tri-complex inhibitor, in patients with RAS mutant pancreatic ductal adenocarcinoma (PDAC)
|
Wolpin, B.
|
|
|
211 |
S1 |
p.
|
artikel
|
| 25 |
507LBA (PB-507) LBA Posters: VRN101099: a novel oral treatment option for patients with advanced solid tumors including brain metastasis driven by HER2 amplification or HER2-activating mutations even with T-DXd resistance
|
Jung, H.R.
|
|
|
211 |
S1 |
p.
|
artikel
|
| 26 |
518LBA (PB-518) LBA Posters: VRTX531, a best-in-class USP1 inhibitor for Homologous Deficient Tumors
|
Surampudi, U.K.
|
|
|
211 |
S1 |
p.
|
artikel
|
| 27 |
10 Oral: AKY-1189, a novel, first-in-class miniprotein radiopharmaceutical designed to deliver Actinium-225 (225Ac) to Nectin-4 expressing tumors with broad therapeutic applications in metastatic urothelial carcinoma (mUC) and other Nectin-4 expressing tumors
|
Sathekge, M.
|
|
|
211 |
S1 |
p.
|
artikel
|
| 28 |
8 Oral: ALTA3263: an oral, KRAS isoform-selective, dual ON/OFF state, noncovalent inhibitor induces regressions across KRAS G12V, G12D, and G12C cancer models
|
Wang, T.
|
|
|
211 |
S1 |
p.
|
artikel
|
| 29 |
9 Oral: BBO-10203, an orally bioavailable small molecule that disrupts the RAS-PI3Kα interaction leading to pAKT and tumor growth inhibition in models of breast, lung and colorectal cancer
|
Simanshu, D.
|
|
|
211 |
S1 |
p.
|
artikel
|
| 30 |
4 Oral: Casdatifan in patients (pts) with previously treated clear cell renal cell cancer (ccRCC) and other solid tumors; preliminary results from ARC- 20: A phase 1, open-label dose-escalation and expansion study
|
Choueiri, T.
|
|
|
211 |
S1 |
p.
|
artikel
|
| 31 |
1 Oral: First Clinical Results from A Phase 1 Trial of PRT3789, a First-in-Class Intravenous SMARCA2 Degrader, in Patients with Advanced Solid Tumors with a SMARCA4 Mutation
|
Yap, T.A.
|
|
|
211 |
S1 |
p.
|
artikel
|
| 32 |
12 Oral: On-target mutations drive resistance to WRN helicase inhibitors in microsatellite unstable colorectal cancer
|
Picco, G.
|
|
|
211 |
S1 |
p.
|
artikel
|
| 33 |
5 Oral: Preliminary Results from a Phase Ia/Ib, Open-label, Multicenter Study of ZL-1310, a DLL3-targeted ADC, to Evaluate the Safety, Tolerability, and Pharmacokinetics in Subjects with Small Cell Lung Cancer - NCT06179069
|
Spira, A.
|
|
|
211 |
S1 |
p.
|
artikel
|
| 34 |
2 Oral: Preliminary results from SEACRAFT-1: An open-label study of naporafenib with trametinib in patients with locally advanced unresectable or metastatic solid tumor malignancies with RAS Q61X mutations
|
Fontana, E.
|
|
|
211 |
S1 |
p.
|
artikel
|
| 35 |
7 Oral: SHR-1701 combined with famitinib for patients with previously treated advanced biliary tract or pancreatic ductal adenocarcinoma: A phase II open-label, single-arm study
|
Yi, L.
|
|
|
211 |
S1 |
p.
|
artikel
|
| 36 |
11 Oral: Transforming cancer care and therapeutic development by predicting individual patient responses to treatment
|
Griffiths, M.
|
|
|
211 |
S1 |
p.
|
artikel
|
| 37 |
3 Oral: Tucatinib and Trastuzumab for Patients With Previously Treated, HER2- Altered Solid Tumors (SGNTUC-019): A Phase 2 Basket Study
|
Nakamura, Y.
|
|
|
211 |
S1 |
p.
|
artikel
|
| 38 |
6 Oral: ZW220, a NaPi2b-directed topoisomerase I inhibitor Antibody-Drug Conjugate, demonstrates compelling preclinical activity in NSCLC, ovarian and uterine cancer models, with a favorable toxicology profile in non-human primates
|
Hernandez, A.
|
|
|
211 |
S1 |
p.
|
artikel
|
| 39 |
119 (PB107): AB801, a potent and highly selective clinical stage AXL inhibitor, sensitizes tumors to standard of care therapies
|
Paprcka, S.
|
|
|
211 |
S1 |
p.
|
artikel
|
| 40 |
91 (PB079): AB521 (Casdatifan) potently and selectively inhibits Hypoxia-Inducible Factor 2 Alpha (HIF-2α) dependent pro-tumorigenic activity
|
Schweickert, P.
|
|
|
211 |
S1 |
p.
|
artikel
|
| 41 |
405 (PB393): A combination of AURK inhibitor and HDAC inhibitor can restrain Anaplastic Thyroid Cancer aggressiveness: a drug repurposing story
|
Manzotti, G.
|
|
|
211 |
S1 |
p.
|
artikel
|
| 42 |
268 (PB256): A combination of omega-3 free fatty acids and catechin modulates the obesity-dependent dysregulation of Wnt/β-catenin/mTOR/Notch1 crosstalk and intestinal stemness in patient-derived 3D intestinal organoids
|
Calafato, G.
|
|
|
211 |
S1 |
p.
|
artikel
|
| 43 |
286 (PB274): A comprehensive biobank of PD3D® models and technology platform for cancer research and therapy response prediction
|
Wedeken, L.
|
|
|
211 |
S1 |
p.
|
artikel
|
| 44 |
255 (PB243): Acquired resistance to immunotherapy by cancer cells’ self-built physical barriers
|
Chen, C.
|
|
|
211 |
S1 |
p.
|
artikel
|
| 45 |
55 (PB043): Activity of CDK4/6 inhibitors in translocation renal cell carcinoma
|
Gupta, S.
|
|
|
211 |
S1 |
p.
|
artikel
|
| 46 |
341 (PB329): Acute BRCAness Induction and AR Signaling Blockage through CDK12/7/9 Degradation Enhances PARP Inhibitor Sensitivity in Prostate Cancer
|
Gui, F.
|
|
|
211 |
S1 |
p.
|
artikel
|
| 47 |
381 (PB369): Adaptive Mechanisms and Synergistic Combinations to Overcome Sotorasib Resistance in KRASG12C-Driven NSCLC
|
Megid, R. Arantes
|
|
|
211 |
S1 |
p.
|
artikel
|
| 48 |
309 (PB297): Addressing Project Optimus: Preclinical, modelling and clinical data to support identification of the Recommended Phase 2 Dose for saruparib
|
Staniszewska, A.
|
|
|
211 |
S1 |
p.
|
artikel
|
| 49 |
172 (PB160): Affimer® Drug Conjugates (AffDC) targeting Fibroblast Activation Protein-α deliver highly toxic warheads to the tumor microenvironment by leveraging the preCISION™ release mechanism
|
Pinto, M.
|
|
|
211 |
S1 |
p.
|
artikel
|
| 50 |
224 (PB212): AI-enhanced high-content imaging to identify effective compound combinations with CDK4/6 inhibitor and endocrine therapy in ER+ HER2- breast cancer
|
Kronstadt, S.
|
|
|
211 |
S1 |
p.
|
artikel
|
| 51 |
308 (PB296): Allometric scaling of preclinical dosimetry for the Nectin-4 miniprotein binders AKY-807 and AKY-1189 accurately predicts human absorbed dose to major organs
|
Ramonaheng, K.
|
|
|
211 |
S1 |
p.
|
artikel
|
| 52 |
35 (PB023): A Multicenter, Open-label Phase 1/2 Study of TYRA 300 in Advanced Urothelial Carcinoma and Other Solid Tumors with Activating FGFR3 Gene Alterations (SURF301)
|
Zhang, A.
|
|
|
211 |
S1 |
p.
|
artikel
|
| 53 |
322 (PB310): A multi-omics approach to identify biomarkers of response to the novel and selective SRC/YES1 inhibitor NXP900
|
King, B.
|
|
|
211 |
S1 |
p.
|
artikel
|
| 54 |
432 (PB420): A multi-omics approach using transcriptomic and spatial analysis to identify predictive immune biomarkers of response and toxicity following chemotherapy in head and neck cancers
|
Juncker-Jensen, A.
|
|
|
211 |
S1 |
p.
|
artikel
|
| 55 |
48 (PB036): A mutant-selective PI3Kα inhibitor suitable for single-agent and combination therapy against PI3CA mutant tumors
|
Fan, X.
|
|
|
211 |
S1 |
p.
|
artikel
|
| 56 |
202 (PB190): Analysis of tumor-specific antigens and neoantigens for cancer treatment
|
Kim, S.
|
|
|
211 |
S1 |
p.
|
artikel
|
| 57 |
323 (PB311): A newly identified OLIG2-STAT5 transcriptional complex regulates the survival and invasion of glioma stem cells
|
Miller, A.
|
|
|
211 |
S1 |
p.
|
artikel
|
| 58 |
449 (PB437): An IND-ready anti-CD4 monoclonal antibody in combination with PD-1 inhibitors for the treatment of solid tumors
|
Nakano, Y.
|
|
|
211 |
S1 |
p.
|
artikel
|
| 59 |
69 (PB057): A novel and potent MAT2A inhibitor, HM100760, demonstrates antitumor activity in MTAP-deleted cancers
|
Kwak, E.J.
|
|
|
211 |
S1 |
p.
|
artikel
|
| 60 |
81 (PB069): A novel BRD4 degrader, MT-4561, exerts continuous anti-tumor effects in various cancer xenograft model and patient derived cells
|
Ooike, S.
|
|
|
211 |
S1 |
p.
|
artikel
|
| 61 |
166 (PB154): A novel HER2 targeted dual-payload ADC, HMBD-802, overcomes resistance to topoisomerase 1 inhibitor ADCs
|
Thakkar, D.
|
|
|
211 |
S1 |
p.
|
artikel
|
| 62 |
183 (PB171): A novel kinase degrader-based payload for the development of potent Degrader Antibody Conjugates (DACs)
|
Uitdehaag, J.C.
|
|
|
211 |
S1 |
p.
|
artikel
|
| 63 |
133 (PB121): A novel pan-RAS inhibitor (ADT-1004) with superior efficacy over mutation-specific KRAS inhibitors in mouse models of pancreatic cancer
|
Bandi, D.S.R.
|
|
|
211 |
S1 |
p.
|
artikel
|
| 64 |
138 (PB126): A novel selective USP1 inhibitor coupled with a novel response biomarker
|
Katzenelenbogen, Y.
|
|
|
211 |
S1 |
p.
|
artikel
|
| 65 |
29 (PB017): A novel small molecule activator of the integrated stress response kinase GCN2 shows potent preclinical antitumor activity as monotherapy and in combination with standard of care agents
|
Al-Ani, G.
|
|
|
211 |
S1 |
p.
|
artikel
|
| 66 |
42 (PB030): A novel small-molecule CBP/p300 HAT domain inhibitor demonstrates potent in vivo activity and a favorable safety profile in preclinical species
|
Hearn, K.
|
|
|
211 |
S1 |
p.
|
artikel
|
| 67 |
103 (PB091): A novel small molecule inhibitor of inactive and active forms of oncogenic mutant KRAS promotes tumor regression in KRASmutated cancer models
|
Weaver, D.
|
|
|
211 |
S1 |
p.
|
artikel
|
| 68 |
358 (PB346): A novel small molecule inhibitor of PARG, YL-18319, promotes tumor regression in BRCAmutated, Homologous Recombination Deficient, and PARP-inhibitor resistant cancer models
|
Weaver, D.
|
|
|
211 |
S1 |
p.
|
artikel
|
| 69 |
362 (PB350): A novel trans-lymphatic route of loco-regional treatment with a single injection providing two routes of treatment
|
Ereth, M.
|
|
|
211 |
S1 |
p.
|
artikel
|
| 70 |
13 (PB001): ANT-045: Demonstrating the promise of better penetrating, safer Antibody Fragment Drug-Conjugates
|
Deonarain, M.
|
|
|
211 |
S1 |
p.
|
artikel
|
| 71 |
155 (PB143): A Phase 1 dose escalation study to evaluate whole body CD8+ T cell distribution using an 18F-labelled PET tracer in patients with solid tumors
|
de Groot, D.J.
|
|
|
211 |
S1 |
p.
|
artikel
|
| 72 |
61 (PB049): A Promising CK1α-selective Molecular Glue Degrader for p53 Reactivation in Hematological and Solid Tumors
|
Kim, H.
|
|
|
211 |
S1 |
p.
|
artikel
|
| 73 |
139 (PB127): ART6043: a first-in-class clinical DNA Polymerase Theta polymerase domain inhibitor for potentiating PARP inhibitor efficacy
|
Robinson, H.
|
|
|
211 |
S1 |
p.
|
artikel
|
| 74 |
428 (PB416): A sorted-cell approach for single-cell TCR α/β and TCR γ/δ immune receptor profiling and immunophenotyping
|
Chenchik, A.
|
|
|
211 |
S1 |
p.
|
artikel
|
| 75 |
426 (PB414): Assessing chordoma heterogeneity: insights from primary and recurrent expression patterns
|
Campilan, B.D.
|
|
|
211 |
S1 |
p.
|
artikel
|
| 76 |
45 (PB033): Assessing the predictive value of genomic drivers for targeted therapy in glioblastoma: Insights from a pre-clinical platform
|
Decarvalho, A.
|
|
|
211 |
S1 |
p.
|
artikel
|
| 77 |
156 (PB144): Association of tumor-infiltrating cells with patient survival and omics data
|
Jeong, E.
|
|
|
211 |
S1 |
p.
|
artikel
|
| 78 |
443 (PB431): A Sub Analysis of Clinical Study of Tomaralimab, a Toll-like Receptor 2 (TLR-2) Antibody, in Patients with Lower Risk Myelodysplastic Syndromes (MDS) That Have Received Prior Hypomethylating Agent (HMA) Therapy
|
Gutierrez, I.
|
|
|
211 |
S1 |
p.
|
artikel
|
| 79 |
331 (PB319): A synergistic two-drug therapy selectively targeting DNA repair dysregulation in p53-deficient cancers
|
Bakin, A.
|
|
|
211 |
S1 |
p.
|
artikel
|
| 80 |
126 (PB114): A TRAILR2/CDH3 bispecific antibody demonstrates selective apoptosis and tumor regression in CDH3-positive pancreatic cancer
|
Jung, P.
|
|
|
211 |
S1 |
p.
|
artikel
|
| 81 |
354 (PB342): ATR inhibition activates cancer cell cGAS/STING-interferon signaling and promotes anti-tumor immunity in small-cell lung cancer
|
Sen, T.
|
|
|
211 |
S1 |
p.
|
artikel
|
| 82 |
348 (PB336): ATRN-119, a Novel Macrocyclic ATR Inhibitor, in Patients with Advanced Solid Malignancies: A Phase 1/2a Trial (ABOYA-119)
|
Mahipal, A.
|
|
|
211 |
S1 |
p.
|
artikel
|
| 83 |
140 (PB128): ATV-1601 is a Potent and Selective Allosteric Inhibitor of AKT1-E17K and Shows Profound and Durable Regressions in AKT1-E17K-Driven Patient Derived Xenograft Models
|
Schinzel, A.C.
|
|
|
211 |
S1 |
p.
|
artikel
|
| 84 |
94 (PB082): AUTX-703, a novel and potent KAT2A and KAT2B protein degrader, induces profound cell state changes and inhibits growth in Small Cell Lung Cancer (SCLC) model systems
|
Sharma, S.
|
|
|
211 |
S1 |
p.
|
artikel
|
| 85 |
333 (PB321): A WRN screening cascade to facilitate novel drug discovery
|
Bing, T.
|
|
|
211 |
S1 |
p.
|
artikel
|
| 86 |
150 (PB138): AZD3470 induces regressions and durable responses in MTAPdeficient tumor models of diverse tumor indications
|
Urosevic, J.
|
|
|
211 |
S1 |
p.
|
artikel
|
| 87 |
468 (PB456): Backfilling Patients in Phase I Dose Escalation Trials: Do it Safely and Efficiently
|
Yuan, Y.
|
|
|
211 |
S1 |
p.
|
artikel
|
| 88 |
374 (PB362): Ba/F3 AKT engineering cell lines, a powerful platform for novel drug discovery
|
Hou, E.
|
|
|
211 |
S1 |
p.
|
artikel
|
| 89 |
259 (PB247): Beyond PD-L1: unraveling the enigma of immunotherapy response in PD-L1 negative (<1%) NSCLC patients through quantification of PD-1/PD-L1 engagement in the tumour microenvironment
|
Miles, J.
|
|
|
211 |
S1 |
p.
|
artikel
|
| 90 |
190 (PB178): BH3 mimetics targeting BCL-XL have efficacy in solid tumors with RB1 loss and replication stress
|
Varkaris, A.
|
|
|
211 |
S1 |
p.
|
artikel
|
| 91 |
329 (PB317): Bioinformatic Analysis of Genetic Ancestry and Germline Variant Correlation in Colombian Women with Triple-Negative Breast Cancer and High-Grade Serous Ovarian Cancer Using Hereditary Cancer Panel
|
Ordonez, Y.T. Zambrano
|
|
|
211 |
S1 |
p.
|
artikel
|
| 92 |
301 (PB289): BQ323636.1 modulates the AR-CDK20 axis to confer doxorubicin resistance in breast cancer
|
Khoo, U.S.
|
|
|
211 |
S1 |
p.
|
artikel
|
| 93 |
408 (PB396): Building insights on the latest novel cancer drugs using pan-cancer ex vivo trials
|
Välimäki, E.
|
|
|
211 |
S1 |
p.
|
artikel
|
| 94 |
159 (PB147): Cancer associated fibroblasts are associated with NK cell exhaustion in Head and Neck Squamous Cell Carcinoma
|
Rodrigues, M.F.
|
|
|
211 |
S1 |
p.
|
artikel
|
| 95 |
392 (PB380): Cancer-associated fibroblasts (CAFs) contractility stimulates cancer cell resistance
|
Zajac, O.
|
|
|
211 |
S1 |
p.
|
artikel
|
| 96 |
265 (PB253): Cancer-associated fibroblasts promote breast cancer metastasis via Gli2-HIF1α/2α-Smad2/3 axis in a 3-D co-culture model
|
Kulkarni, P.
|
|
|
211 |
S1 |
p.
|
artikel
|
| 97 |
283 (PB271): CancerModels.Org - an open global cancer research platform for patient-derived cancer models.
|
Perova, Z.
|
|
|
211 |
S1 |
p.
|
artikel
|
| 98 |
163 (PB151): Cancer Neutrophil Encyclopedia: A Deep Dive into Antigen-Presenting Warriors
|
Wu, Y.
|
|
|
211 |
S1 |
p.
|
artikel
|
| 99 |
450 (PB438): CAPTN-3: A novel platform of conditionally activated T cell and NK cell engagers
|
Reuveni, H.
|
|
|
211 |
S1 |
p.
|
artikel
|
| 100 |
86 (PB074): CDCP1/mitochondrial Src axis induces oxidative phosphorylation fueling triple-negative breast cancer migration
|
Razorenova, O.
|
|
|
211 |
S1 |
p.
|
artikel
|
| 101 |
104 (PB092): CDK2 heterobifunctional degraders co-degrade CDK2 and Cyclin E resulting in efficacy in CCNE1-amplified and overexpressed cancers
|
Kwiatkowski, N.
|
|
|
211 |
S1 |
p.
|
artikel
|
| 102 |
369 (PB357): Cell Line Panel with HiBiT-Tagged Endogenous Proteins: A Leap Forward in PROTAC Drug Discovery
|
Hou, E.
|
|
|
211 |
S1 |
p.
|
artikel
|
| 103 |
151 (PB139): CFON-026, a best-in-class macrocyclic non-covalent inhibitor of BTK (WT) and all clinically relevant BTK resistance mutations
|
Van Mil, Y.
|
|
|
211 |
S1 |
p.
|
artikel
|
| 104 |
75 (PB063): Challenging immortality: investigating the efficacy of novel telomerase inhibitors on telomere disruption and cancer elimination
|
Maciejewska, N.
|
|
|
211 |
S1 |
p.
|
artikel
|
| 105 |
423 (PB411): Characterization and evaluation of the protein kinase BUB1B as therapeutic target in ewing sarcoma
|
Schaefer, C.
|
|
|
211 |
S1 |
p.
|
artikel
|
| 106 |
383 (PB371): Characterization of cancer cell lines selected for resistance to growth factor receptor tyrosine kinase inhibitors and signal transduction therapies
|
Melis, J.
|
|
|
211 |
S1 |
p.
|
artikel
|
| 107 |
222 (PB210): Chromatin remodeling agents enhance efficacy of 17b-estradiol therapy for endocrine-resistant ER+ breast cancer
|
Johnson, A.
|
|
|
211 |
S1 |
p.
|
artikel
|
| 108 |
51 (PB039): Clinical Pharmacokinetic/Pharmacodynamic (PK/PD) Relationship for Casdatifan (AB521), a Small Molecule Inhibitor of HIF-2α, Confirms Best-in-class Potential in Treatment of Renal Cell Carcinoma
|
Ghasemi, M.
|
|
|
211 |
S1 |
p.
|
artikel
|
| 109 |
221 (PB209): Combination effect of the KRAS G12D-specific degrader ASP3082 with Cetuximab in xenograft models of colorectal and pancreatic cancer cells with KRAS G12D mutation
|
Iguchi, K.
|
|
|
211 |
S1 |
p.
|
artikel
|
| 110 |
279 (PB267): Combination of genomics-based targeted therapy and standard chemotherapy in xenografts derived from patients with non-small cell lung cancer
|
Decaudin, D.
|
|
|
211 |
S1 |
p.
|
artikel
|
| 111 |
300 (PB288): Combination of RAS(ON) Multi-Selective and G12D-Selective Inhibitors Improves Antitumor Activity and Enhances Antitumor Immunity in Preclinical Models of KRASG12D-Driven Cancers
|
Jiang, L.
|
|
|
211 |
S1 |
p.
|
artikel
|
| 112 |
67 (PB055): Combined cellular and biochemical profiling of BTK inhibitor nemtabrutinib reveals potential application in FGFR-driven cancers
|
Kluitmans, D.
|
|
|
211 |
S1 |
p.
|
artikel
|
| 113 |
218 (PB206): Combining next-generation BTK and MALT1 inhibitors to enhance efficacy and therapeutic utility in B-cell malignancies
|
Payne, A.
|
|
|
211 |
S1 |
p.
|
artikel
|
| 114 |
230 (PB218): Combining OP-3136, a KAT6 inhibitor, with endocrine therapy and CDK4/6 inhibitor enhances anti-tumor activity in ER+/HER2- breast cancer models
|
Palanisamy, G.
|
|
|
211 |
S1 |
p.
|
artikel
|
| 115 |
212 (PB200): Combining palazestrant, a CERAN, and capivasertib, a pan-AKT inhibitor, enhances tumor suppression in ER+/HER2- breast cancer models
|
Barratt, S.
|
|
|
211 |
S1 |
p.
|
artikel
|
| 116 |
211 (PB199): Combining palazestrant, a CERAN, and everolimus, an mTOR inhibitor, enhances tumor suppression in ER+/HER2- breast cancer models
|
Barratt, S.
|
|
|
211 |
S1 |
p.
|
artikel
|
| 117 |
277 (PB265): Comparative analysis of immune responses in a 3D ex vivo patient tissue platform across diverse cancer types
|
Aksoy, E. Kaya
|
|
|
211 |
S1 |
p.
|
artikel
|
| 118 |
325 (PB313): Comparative Analysis of Pathogenic Variant Detection in Patients with Multiple Primary Cancers (MPCs): Disease-Specific Guidelines vs. MPC-Based Approaches
|
Shin, K.
|
|
|
211 |
S1 |
p.
|
artikel
|
| 119 |
313 (PB301): Comparison of single agent versus combination activity of enfortumab vedotin (EV) and sacituzumab govitecan (SG) in a panel of bladder cancer XPDX models
|
Simonson, A.
|
|
|
211 |
S1 |
p.
|
artikel
|
| 120 |
431 (PB419): Comprehensive analysis of the diversity of gastric cancer genomes and cancer-stromal interactions by single-cell spatial transcriptomics
|
Ishikawa, S.
|
|
|
211 |
S1 |
p.
|
artikel
|
| 121 |
413 (PB401): Comprehensive characterization of CDK inhibitors using a complete panel of all 20 human cyclin-dependent kinases
|
Müller, D.
|
|
|
211 |
S1 |
p.
|
artikel
|
| 122 |
324 (PB312): Comprehensive Omics and Phenotypic Data Integration for Enhanced Drug Target and Biomarker Discovery in Cancer
|
Park, Y.
|
|
|
211 |
S1 |
p.
|
artikel
|
| 123 |
373 (PB361): Computational design of EGFR targeted macrocyclic peptides
|
Tydings, C.
|
|
|
211 |
S1 |
p.
|
artikel
|
| 124 |
312 (PB300): Concurrent inhibition of KRAS G12C and ERK1/2 overcomes acquired resistance to KRAS G12C inhibitors (G12Cis) conferred by various genetic alterations
|
Wang, W.
|
|
|
211 |
S1 |
p.
|
artikel
|
| 125 |
200 (PB188): Cornulin, detected through electroporation based molecular sampling, discriminates between human basal cell carcinoma and squamous cell carcinoma
|
Golberg, A.
|
|
|
211 |
S1 |
p.
|
artikel
|
| 126 |
352 (PB340): Covalent PARG inhibitors show sustained target engagement and superior anticancer activity
|
Patra, S.
|
|
|
211 |
S1 |
p.
|
artikel
|
| 127 |
241 (PB229): Critical role of cyclin-G associated kinase (GAK) in mitotic progression defines a new target for cancer therapy linked to deficiency of the RB tumor suppressor
|
Lightfuss, O.
|
|
|
211 |
S1 |
p.
|
artikel
|
| 128 |
454 (PB442): Cross-HLA targeting of synthetic neoepitopes with T cell engagers to eradicate KRAS-G12C inhibitor-resistant cancers
|
Maso, L.
|
|
|
211 |
S1 |
p.
|
artikel
|
| 129 |
370 (PB358): Cyclin K degraders built on a purine scaffold
|
Jorda, R.
|
|
|
211 |
S1 |
p.
|
artikel
|
| 130 |
240 (PB228): Data analysis and model evaluation of chemotherapy induced neutropenia – results from the PARTNER trial
|
Hodson, D.
|
|
|
211 |
S1 |
p.
|
artikel
|
| 131 |
181 (PB169): DB-1419, a first-in-class bispecific ADC targeting B7-H3 and PD-L1 with a DNA topoisomerase I inhibitor, exhibits promising efficacy and safety in preclinical models
|
Li, C.
|
|
|
211 |
S1 |
p.
|
artikel
|
| 132 |
180 (PB168): DB-1314, a novel DLL3-targeting ADC with DNA topoisomerase I inhibitor, exhibits promising therapeutic efficacy and safety profile in preclinical
|
Lin, S.
|
|
|
211 |
S1 |
p.
|
artikel
|
| 133 |
153 (PB141): DCBCI2203, a novel protein degrader targeting KRAS G12D/V
|
Yang, Y.N.
|
|
|
211 |
S1 |
p.
|
artikel
|
| 134 |
314 (PB302): Deciphering and targeting the schwannoma-neuron-macrophage crosstalk for the treatment of schwannomatosis and associated pain
|
Yin, Z.
|
|
|
211 |
S1 |
p.
|
artikel
|
| 135 |
379 (PB367): Decoding the Pivotal Roles of BCL10 Activating Mutations in DLBCL Drug Resistance and Lymphomagenesis
|
Chahar, D.
|
|
|
211 |
S1 |
p.
|
artikel
|
| 136 |
267 (PB255): Defining the spectrum of response and radiosensitizing potential of WSD0628 in brain patient-derived xenografts (PDX) models
|
Burgenske, D.
|
|
|
211 |
S1 |
p.
|
artikel
|
| 137 |
448 (PB436): Deletion of SUZ12 improves cancer cell immunogenicity
|
Morales, M.L. Orozco
|
|
|
211 |
S1 |
p.
|
artikel
|
| 138 |
361 (PB349): Dendrimers in cancer therapy: exploring protein corona interactions for enhanced drug delivery and theragnostic applications
|
Cavalieri, G.
|
|
|
211 |
S1 |
p.
|
artikel
|
| 139 |
368 (PB356): Design and functional characterization of a first-in-class irreversible inhibitor of HOIL-1-interacting protein (HOIP) with selective antitumor activity against B-cell non-Hodgkin lymphoma
|
de Pablo, G. Gorjón
|
|
|
211 |
S1 |
p.
|
artikel
|
| 140 |
25 (PB013): Design, development and characterization of novel CAR T cells targeting globo-H for solid tumor cell therapy
|
Putti, F.
|
|
|
211 |
S1 |
p.
|
artikel
|
| 141 |
412 (PB400): Design, synthesis and biological evaluation of novel hybrids of Quinazoline-Chalcones as potent inducers of cell-cycle arrest and apoptosis through DNA damage and ATR inhibition
|
Stringhetta, G.
|
|
|
211 |
S1 |
p.
|
artikel
|
| 142 |
464 (PB452): Determination of the phase 2 dose of AU-007, an AI-designed human monoclonal antibody that redirects IL-2 to T-effector cells
|
Wyant, T.
|
|
|
211 |
S1 |
p.
|
artikel
|
| 143 |
22 (PB010): Developing amouse model for chordoma: comparing the effectiveness of iliac crest and flank tumor implantation
|
Godinez, C.
|
|
|
211 |
S1 |
p.
|
artikel
|
| 144 |
287 (PB275): Developing novel AR mutant prostate cancer models for CRPC related drug discovery
|
Xu, N.
|
|
|
211 |
S1 |
p.
|
artikel
|
| 145 |
336 (PB324): Development and testing of a first-in-class series of macrocyclic ATR inhibitors for cancer treatment
|
Rocca, S.
|
|
|
211 |
S1 |
p.
|
artikel
|
| 146 |
269 (PB257): Development of a precision medicine platform for paediatric acute myeloid leukaemia
|
Connerty, P.
|
|
|
211 |
S1 |
p.
|
artikel
|
| 147 |
274 (PB262): Development of Patient-Derived Colorectal Cancer Xenograft and Organoid Models with Acquired Resistance to KRAS G12C Inhibitors
|
Hua, L.
|
|
|
211 |
S1 |
p.
|
artikel
|
| 148 |
97 (PB085): Development of SATB2 inhibitor for the treatment of hepatocellular carcinoma
|
Srivastava, R.
|
|
|
211 |
S1 |
p.
|
artikel
|
| 149 |
26 (PB014): Development of Tumour-specific CD146 CAR-T Cells for Targeted Cancer Immunotherapy of Solid Tumours
|
Uzuner, E.
|
|
|
211 |
S1 |
p.
|
artikel
|
| 150 |
157 (PB145): Dietary sugar potentiates tobacco carcinogen-induced lung cancer development and progression by inducing the recruitment and protumoral polarization of macrophages
|
Lee, H.Y.
|
|
|
211 |
S1 |
p.
|
artikel
|
| 151 |
201 (PB189): Different expression of CDK4 and CDK6 among B-cell non-Hodgkin lymphomas as a marker of sensitivity to CDK4/6 inhibitors
|
Veselá, D.
|
|
|
211 |
S1 |
p.
|
artikel
|
| 152 |
89 (PB077): Discovery and cellular delivery of BCL3 inhibitors for the potential treatment of advanced solid tumours with unmet medical need
|
Ruzic, D.
|
|
|
211 |
S1 |
p.
|
artikel
|
| 153 |
339 (PB327): Discovery and characterisation of DNA polymerase theta inhibitors for the treatment of cancer
|
Hollick, J.
|
|
|
211 |
S1 |
p.
|
artikel
|
| 154 |
40 (PB028): Discovery and characterization of a high orally available small molecule inhibitor of KRASG12D
|
Zhang, Y.
|
|
|
211 |
S1 |
p.
|
artikel
|
| 155 |
99 (PB087): Discovery and characterization of BRD4 degraders utilizing diverse E3 ligases for treatment of acute myeloid leukemia (AML).
|
Hamada, M.
|
|
|
211 |
S1 |
p.
|
artikel
|
| 156 |
84 (PB072): Discovery and characterization of potent inhibitors of the RNA editing enzyme ADAR1
|
Pollard, J.
|
|
|
211 |
S1 |
p.
|
artikel
|
| 157 |
357 (PB345): Discovery and development of IMP1734 (EIK1003), a potent and selective PARP1 inhibitor
|
Cai, S.X.
|
|
|
211 |
S1 |
p.
|
artikel
|
| 158 |
118 (PB106): Discovery and pre-clinical development of AKY-1189, a potent and selective Nectin-4 miniprotein binder optimized for use as a targeted radiopharmaceutical
|
Way, J.
|
|
|
211 |
S1 |
p.
|
artikel
|
| 159 |
401 (PB389): Discovery of a covalent inhibitor targeting the undruggable oncogene cMyc
|
Hao, L.
|
|
|
211 |
S1 |
p.
|
artikel
|
| 160 |
372 (PB360): Discovery of a highly MTA-synergistic series of PRMT5 inhibitors for the treatment of MTAP-deficient tumors by virtual screening technology
|
Parr, B.
|
|
|
211 |
S1 |
p.
|
artikel
|
| 161 |
228 (PB216): Discovery of Androgen Metabolism Enhancing Androgen Receptor Antagonists for the Treatment of Castration-Resistant prostate Cancer
|
Narayanan, R.
|
|
|
211 |
S1 |
p.
|
artikel
|
| 162 |
442 (PB430): Discovery of a Novel Covalent ADAR1 Inhibitor
|
Wang, C.
|
|
|
211 |
S1 |
p.
|
artikel
|
| 163 |
402 (PB390): Discovery of a Novel Covalent PAX8 Inhibitor
|
McKinney, A.
|
|
|
211 |
S1 |
p.
|
artikel
|
| 164 |
141 (PB129): Discovery of a novel KAT6A/B inhibitor with anti-tumor activity coupled with novel response biomarkers
|
Seger, E.
|
|
|
211 |
S1 |
p.
|
artikel
|
| 165 |
167 (PB155): Discovery of first-in-class precision antibody drug conjugates with a potent SMARCA2/4 dual degrader payload that safely achieve maximal and tumor specific degradation and efficacy in mouse models
|
Carter, J.
|
|
|
211 |
S1 |
p.
|
artikel
|
| 166 |
31 (PB019): Discovery of HM-279, a novel, potent and orally active inhibitor of ALK5 for cancer immunotherapy
|
Arai, M.
|
|
|
211 |
S1 |
p.
|
artikel
|
| 167 |
14 (PB002): Discovery of NKT3964: a first-in-class, highly potent and selective, orally bioavailable CDK2 PROTAC degrader for cancer therapy
|
Geng, J.
|
|
|
211 |
S1 |
p.
|
artikel
|
| 168 |
340 (PB328): Discovery of NODX-010, a novel, potent PARG inhibitor demonstrating robust in vivo efficacy and the potential for new clinical settings that benefit patients with tumours resistant to PARP inhibitors
|
James, D.
|
|
|
211 |
S1 |
p.
|
artikel
|
| 169 |
32 (PB020): Discovery of novel MTA-cooperative PRMT5 inhibitors as targeted therapeutics for MTAP-deleted cancers
|
Radzimierski, A.
|
|
|
211 |
S1 |
p.
|
artikel
|
| 170 |
345 (PB333): Discovery of novel series of PKMYT1 inhibitors forcombination therapy with antibody-drug conjugates
|
Marais, R.
|
|
|
211 |
S1 |
p.
|
artikel
|
| 171 |
109 (PB097): Discovery of NTS071, an orally bioavailable, highly potent and selective small molecule p53 Y220C reactivator
|
Yu, L.
|
|
|
211 |
S1 |
p.
|
artikel
|
| 172 |
106 (PB094): Discovery of potent, selective, and orally bioavailable HER2 tyrosine kinase inhibitors targeting HER2 exon20 insertion mutants and HER2WT
|
Yoo, H.S.
|
|
|
211 |
S1 |
p.
|
artikel
|
| 173 |
147 (PB135): Discovery of SGR-3515, a first-in-class Wee1/Myt1 inhibitor with differentiated pharmacological properties in xenograft tumor models
|
Sun, S.
|
|
|
211 |
S1 |
p.
|
artikel
|
| 174 |
107 (PB095): Discovery of WRN inhibitors as targeted therapy in the treatment of microsatellite unstable (MSI-H) tumors
|
Zawadzka, M.
|
|
|
211 |
S1 |
p.
|
artikel
|
| 175 |
122 (PB110): Disrupting ion homeostasis of specific cellular organelles as a new therapeutic strategy for cancer treatment
|
Fontova, P.
|
|
|
211 |
S1 |
p.
|
artikel
|
| 176 |
243 (PB231): DNA minor groove inhibitor, lurbinectedin, induces multimodal immune activation and augments the anti-tumor immune response in small-cell lung cancer
|
Sen, T.
|
|
|
211 |
S1 |
p.
|
artikel
|
| 177 |
189 (PB177): Downregulation of microRNA-214-3p by long non-coding RNA DNAJC3-As1 promotes carboplatin resistance in esophageal cancer cells through the overexpression of the anti-apoptotic protein c-IAP1
|
Phatak, P.
|
|
|
211 |
S1 |
p.
|
artikel
|
| 178 |
149 (PB137): Dual metastasis- and tumor-inhibitory efficacy of a first-in-class metastasis-initiating-cell-targeted therapeutic antibody
|
Tsai, K.K.C.
|
|
|
211 |
S1 |
p.
|
artikel
|
| 179 |
219 (PB207): Dual Targeting of BRAF-V600E and Ferroptosis Results in Synergistic Anticancer Activity via Iron Overload and Enhanced Oxidative Stress
|
Hu, J.
|
|
|
211 |
S1 |
p.
|
artikel
|
| 180 |
214 (PB202): Dual targeting of DNA damage repair pathway by BET and CDK4/6 inhibitors synergistically inhibits breast cancer
|
Chi, S.
|
|
|
211 |
S1 |
p.
|
artikel
|
| 181 |
76 (PB064): E7386 enhances both lenvatinib and anti-PD1 antitumor activity in HCC
|
Badalian, A. Mesropian
|
|
|
211 |
S1 |
p.
|
artikel
|
| 182 |
65 (PB053): Effect of tasurgratinib as an orally available FGFR1-3 inhibitor on resistance to a CDK4/6 inhibitor and endocrine therapy in ER(+)/HER2 (-) breast cancer preclinical models
|
Kawano, S.
|
|
|
211 |
S1 |
p.
|
artikel
|
| 183 |
304 (PB292): Effects of Nectin-4 targeted Bicycle Toxin Conjugate, zelenectide pevedotin (BT8009), and enfortumab vedotin on a human corneal tissue model
|
Kristensson, J.
|
|
|
211 |
S1 |
p.
|
artikel
|
| 184 |
130 (PB118): Efficacy of Quaratusugene Ozeplasmid TUSC2 Gene Therapy in Glioblastoma
|
Arrigo, A.
|
|
|
211 |
S1 |
p.
|
artikel
|
| 185 |
110 (PB098): Efficacy of WNTinib, a novel selective therapeutic for CTNNB1-mutant tumors, in preclinical models of hepatoblastoma
|
Balaseviciute, U.
|
|
|
211 |
S1 |
p.
|
artikel
|
| 186 |
456 (PB444): EG-70 (detalimogene voraplasmid), a novel, investigational non-viral immunotherapy for non-muscle-invasive bladder cancer: mechanism of action and translation to the clinic
|
Sullivan, J.
|
|
|
211 |
S1 |
p.
|
artikel
|
| 187 |
327 (PB315): EGFR missense mutation(s) regulate glioma stem cells maintenance and therapeutic resistance through independent pathways
|
Weaver, S.
|
|
|
211 |
S1 |
p.
|
artikel
|
| 188 |
466 (PB454): Eligibility Criteria in Phase 1 Cancer Trials: Do Eligibility Lab Values of Albumin, Absolute Lymphocyte Count, Renal Function and ECOG Performance Status Really Impact Patient Suitability
|
Charkhchi, P.
|
|
|
211 |
S1 |
p.
|
artikel
|
| 189 |
391 (PB379): Elucidating molecular differences between cytoprotective and cytotoxic autophagy in lung cancer cell models
|
García, A.A. Torres
|
|
|
211 |
S1 |
p.
|
artikel
|
| 190 |
281 (PB269): Emerging role of HOXB9 transcription factor in cutaneous melanoma
|
Montico, B.
|
|
|
211 |
S1 |
p.
|
artikel
|
| 191 |
457 (PB445): Engineering smart molecules to stimulate the immune system
|
Timiraos, A.
|
|
|
211 |
S1 |
p.
|
artikel
|
| 192 |
284 (PB272): Enhancing Biobank Quality Control: An NGS-QC-PANEL as a Superior Alternative to STR Assays for Large-Scale Sample Authentication
|
Qian, W.
|
|
|
211 |
S1 |
p.
|
artikel
|
| 193 |
261 (PB249): ENPP1 is an innate immune checkpoint of the anticancer cGAMPSTING pathway in breast cancer
|
Wang, S.
|
|
|
211 |
S1 |
p.
|
artikel
|
| 194 |
317 (PB305): Epigenomics of the chordoma phenotype transformation
|
Arditi, J.
|
|
|
211 |
S1 |
p.
|
artikel
|
| 195 |
134 (PB122): ERAS-801: a selective brain-penetrant EGFR inhibitor with improved activity against EGFR extracellular domain-mutant glioblastoma
|
Nathanson, D.
|
|
|
211 |
S1 |
p.
|
artikel
|
| 196 |
386 (PB374): Establishment and characterization of XPDX models with acquired or conditioned resistance to KRASG12C inhibitors
|
Moriarty, A.
|
|
|
211 |
S1 |
p.
|
artikel
|
| 197 |
272 (PB260): Establishment and evaluation of radioresistant models from patient derived tissue
|
Cold, S.
|
|
|
211 |
S1 |
p.
|
artikel
|
| 198 |
207 (PB195): Evaluating the Use of Merlin-YAP Dual-label Immunohistochemistry for Predicting Response to TEAD Inhibitor VT3989
|
Tang, T.
|
|
|
211 |
S1 |
p.
|
artikel
|
| 199 |
184 (PB172): Evaluation of a Novel and Highly Efficacious Anti-HER2 Antibody-Drug Conjugate for HER2-Positive Breast Cancer Treatment
|
Vuist, I.
|
|
|
211 |
S1 |
p.
|
artikel
|
| 200 |
197 (PB185): Evaluation of serum level of WT1 gene protein in the diagnosis of ovarian cancer
|
Dubey, H.
|
|
|
211 |
S1 |
p.
|
artikel
|
| 201 |
229 (PB217): Evaluation of the combined antiproliferative effects of Pan-RAF Inhibitor AZ-628 and MEK1 Inhibitor AZD-6244 across a diverse range of tumor cell lines
|
Obier, N.
|
|
|
211 |
S1 |
p.
|
artikel
|
| 202 |
470 (PB458): Exploring oncometabolite pathways in pediatric brain tumors as an actionable target to improve viroimmunotherapy
|
Moure, M. Garcia
|
|
|
211 |
S1 |
p.
|
artikel
|
| 203 |
406 (PB394): Exploring peptide derived from Signaling Lymphocytic Activation Molecule-1 as a novel anti-cancer treatment for multiple myeloma
|
Mestvedt, I.
|
|
|
211 |
S1 |
p.
|
artikel
|
| 204 |
319 (PB307): Exploring Potential Synthetic Epigenetic Lethality (SEL) Partners of ARID1A in Breast Cancer Using Epigenome-wide CRISPR-Cas9 Knockout Library (EPIKOL) Screening
|
Guzar, E.
|
|
|
211 |
S1 |
p.
|
artikel
|
| 205 |
417 (PB405): Exploring Synthetic Lethality and novel drug combinations in Patient-Derived Cells
|
Dulęba, M.
|
|
|
211 |
S1 |
p.
|
artikel
|
| 206 |
463 (PB451): Exploring the potential of TCX-101, an antibody targeting a tumorassociated carbohydrate antigen, as a bispecific T cell engager for the treatment of solid tumors
|
Winkler, W.
|
|
|
211 |
S1 |
p.
|
artikel
|
| 207 |
85 (PB073): Exploring the therapeutic potential of cell-penetrating peptide-assisted siRNA delivery to target Lactate dehydrogenase C (LDHC) in triplenegative breast Cancer
|
Qasem, H.
|
|
|
211 |
S1 |
p.
|
artikel
|
| 208 |
173 (PB161): Ex vivo 3D micro tumor testing platform to guide patient stratification for clinical development of ADCs
|
Koedoot, E.
|
|
|
211 |
S1 |
p.
|
artikel
|
| 209 |
302 (PB290): Ex vivo patient micro tumor testing to characterize and predict immunotherapy drug responses
|
Koedoot, E.
|
|
|
211 |
S1 |
p.
|
artikel
|
| 210 |
296 (PB284): EZH2 is a druggable target of resistance to CDK4/6 inhibitors in breast cancer
|
Gazzah, E. El
|
|
|
211 |
S1 |
p.
|
artikel
|
| 211 |
59 (PB047): Fadraciclib, an oral CDK2/9 inhibitor, in patients with advanced solid tumors and lymphoma with CDKN2A and/or CDKN2B genetic alterations
|
Piha-Paul, S.
|
|
|
211 |
S1 |
p.
|
artikel
|
| 212 |
363 (PB351): Ferrous Iron Reactive (FIRE) delivery of diagnostic or therapeutic agents
|
Fontaine, S.
|
|
|
211 |
S1 |
p.
|
artikel
|
| 213 |
52 (PB040): FGF signaling blockade hampers the growth of c-Myc-driven aggressive B-cell non-Hodgkin lymphoma
|
Faletti, J.
|
|
|
211 |
S1 |
p.
|
artikel
|
| 214 |
459 (PB447): Fibrinogen-like protein 2 (FGL2) is a multifaceted immune checkpoint with potential therapeutic application in B-cell non-Hodgkin Lymphomas
|
Valero, J.G.
|
|
|
211 |
S1 |
p.
|
artikel
|
| 215 |
146 (PB134): First disclosure of AZD3470, a highly potent MTA-cooperative PRMT5 inhibitor in PRIMROSE and PRIMAVERA clinical studies
|
Smith, J.
|
|
|
211 |
S1 |
p.
|
artikel
|
| 216 |
114 (PB102): First-in-class TET2 activator as a new therapeutic strategy to fight cancer
|
Aguilar, D.
|
|
|
211 |
S1 |
p.
|
artikel
|
| 217 |
98 (PB086): First-in-human, phase 1 study of a selective RET inhibitor, LOXO-260, in patients with RET inhibitor refractory, RET-altered cancers
|
Subbiah, V.
|
|
|
211 |
S1 |
p.
|
artikel
|
| 218 |
444 (PB432): First-in-human phase 1 study of RGT-264, a potent hematopoietic progenitor kinase 1 (HPK1) inhibitor in patients (pts) with advanced solid tumors
|
Ge, X.
|
|
|
211 |
S1 |
p.
|
artikel
|
| 219 |
451 (PB439): First results of a Phase 1 study evaluating safety, PK, PD and clinical activity of STC-15, aMETTL3 inhibitor, in patients with advanced malignancies
|
Rodon, J.
|
|
|
211 |
S1 |
p.
|
artikel
|
| 220 |
164 (PB152): Generation of a panel of differentiated cytotoxic payloads for antibody drug conjugates
|
Arvedson, T.
|
|
|
211 |
S1 |
p.
|
artikel
|
| 221 |
266 (PB254): Gene therapy approach mediated by placental mesenchymal stromal cell-secreted extracellular vesicles in the treatment of pancreatic cancer
|
Buocikova, V.
|
|
|
211 |
S1 |
p.
|
artikel
|
| 222 |
382 (PB370): Genome-wide CRISPR screens identify the YAP/TEAD axis as a driver of persister cells in EGFR mutant lung cancer
|
Pfeifer, M.
|
|
|
211 |
S1 |
p.
|
artikel
|
| 223 |
20 (PB008): Genomic analysis of canine cancer cell lines reveals molecular targets for comparative oncology
|
Duval, D.
|
|
|
211 |
S1 |
p.
|
artikel
|
| 224 |
404 (PB392): Genomics-based approach to drug testing in novel patient-derived xenograft models of undifferentiated pleomorphic sarcoma
|
Manasterski, P.
|
|
|
211 |
S1 |
p.
|
artikel
|
| 225 |
186 (PB174): GenTAP: a GenSci TOP1i ADC platform with improved plasma stability, superior bystander killing and better in vivo efficacy
|
Li, Q.
|
|
|
211 |
S1 |
p.
|
artikel
|
| 226 |
437 (PB425): Glycation status in breast and endometrial tumors assessed based on the expression of MAGE – the novel glycation end-products and RAGE – receptor for advanced glycation-end products
|
Staniszewska, M.
|
|
|
211 |
S1 |
p.
|
artikel
|
| 227 |
416 (PB404): G protein nucleolar 3 promotes cell-cycle progression and suppresses immune response signaling in castrate-resistant prostate cancer by collaborating with the androgen-receptor
|
Cheung, E.
|
|
|
211 |
S1 |
p.
|
artikel
|
| 228 |
441 (PB429): GRC 70267, a novel first-generation small molecule degrader of IRAK-M with anti-tumor activity
|
Gowda, N.
|
|
|
211 |
S1 |
p.
|
artikel
|
| 229 |
129 (PB117): Harnessing hypoxia: CP-506’s journey from bench to bedside in cancer therapy
|
Liu, E.
|
|
|
211 |
S1 |
p.
|
artikel
|
| 230 |
318 (PB306): HER2 overexpression initiates breast tumorigenesis non-cellautonomously by inducing oxidative stress in the tissue microenvironment
|
Gurler, S.B.
|
|
|
211 |
S1 |
p.
|
artikel
|
| 231 |
174 (PB162): HER2-targeting immunocytokine stimulated anti-tumor immune profile and marked efficacy in mouse tumor model
|
Lan, K.H.
|
|
|
211 |
S1 |
p.
|
artikel
|
| 232 |
397 (PB385): High-Throughput 2D and 3D Cell Panel screening to facilitate RAS target drug Discovery and development
|
Bing, T.
|
|
|
211 |
S1 |
p.
|
artikel
|
| 233 |
262 (PB250): High-throughput fluorescence-based screening assay for indoleamine 2,3-dioxygenase 2 (IDO2)
|
Willemsen-Seegers, N.
|
|
|
211 |
S1 |
p.
|
artikel
|
| 234 |
398 (PB386): High throughput screening identified the activity of histone deacetylase inhibitors in patient-derived models of undifferentiated pleomorphic sarcoma
|
Danks, M.
|
|
|
211 |
S1 |
p.
|
artikel
|
| 235 |
245 (PB233): Histone methylation changes of H3K9 and H3K36 in PBMCs as pharmacodynamic biomarkers for Zavondemstat (TACH101), a paninhibitor of KDM4 histone lysine demethylase
|
Chandhasin, C.
|
|
|
211 |
S1 |
p.
|
artikel
|
| 236 |
82 (PB070): HM99462, a novel SOS1 inhibitor, induces tumor regression and synergistic effect with KRAS or EGFR targeted therapy in NSCLC
|
Park, W.
|
|
|
211 |
S1 |
p.
|
artikel
|
| 237 |
254 (PB242): HMPL-500, a potent and selective EZH1/EZH2 dual inhibitor, demonstrates superior anti-tumor activity in preclinical models of hematological malignancies and solid tumors
|
Ge, L.
|
|
|
211 |
S1 |
p.
|
artikel
|
| 238 |
400 (PB388): Hybrid Molecules Targeting EGFR and Promoting DNA Damage: A Promising Approach in Colorectal and Head and Neck Cancer
|
Gomes, I.
|
|
|
211 |
S1 |
p.
|
artikel
|
| 239 |
434 (PB422): Hypoxia-Induced Autophagic Degradation of Connexin 43: Implications for Cancer Therapy
|
Lee, S.
|
|
|
211 |
S1 |
p.
|
artikel
|
| 240 |
349 (PB337): IDE161, a potential first-in-class clinical candidate PARG inhibitor, selectively targets solid tumors with replication stress and DNA repair vulnerabilities
|
Munoz, D.M.
|
|
|
211 |
S1 |
p.
|
artikel
|
| 241 |
63 (PB051): Identification and a mode of action of bisabosqual A, a novel asparagine synthetase (ASNS) inhibitor, towards the development of molecular-targeted anticancer drug
|
Kakeya, H.
|
|
|
211 |
S1 |
p.
|
artikel
|
| 242 |
415 (PB403): Identification and characterization of novel mTOR splicing isoform
|
Alharbi, Z. Alraddadi
|
|
|
211 |
S1 |
p.
|
artikel
|
| 243 |
419 (PB407): Identification and target deconvolution of novel small molecule inhibitors of oncogenic YAP1/TAZ activity
|
Lange, M.
|
|
|
211 |
S1 |
p.
|
artikel
|
| 244 |
36 (PB024): Identification of allosteric inhibitors targeting Discoidin Domain Receptor 2 (DDR2)
|
Cano, S.
|
|
|
211 |
S1 |
p.
|
artikel
|
| 245 |
120 (PB108): Identification of a Potent KRAS Dual On/Off Inhibitor with Selectivity for Mutant KRAS over HRAS and NRAS
|
Fischer, J.
|
|
|
211 |
S1 |
p.
|
artikel
|
| 246 |
79 (PB067): Identification of biomarkers of response and the mechanism of action of a selective androgen receptor modulator in estrogen receptorpositive breast cancer patient-derived xenografts
|
Monserrat, L.
|
|
|
211 |
S1 |
p.
|
artikel
|
| 247 |
28 (PB016): Identification of biomarkers predictive of response to ASTX295, a nextgeneration MDM2 antagonist, in solid tumors carrying wild-type p53
|
Ahn, M.
|
|
|
211 |
S1 |
p.
|
artikel
|
| 248 |
248 (PB236): Identification of inhibitors of BCL2 family members and glucose metabolism as effective combination partners of belinostat in T-cell lymphoma (TCL) cell lines
|
Mensah, A.A.
|
|
|
211 |
S1 |
p.
|
artikel
|
| 249 |
430 (PB418): Identification of Molecular Profiles of Triple-Negative Breast Cancer in Colombian Patients and Their Association with Immune Infiltration and Disease Prognosis
|
Caro, C.A. Huertas
|
|
|
211 |
S1 |
p.
|
artikel
|
| 250 |
411 (PB399): Identification of novel therapeutic targets for pancreatic ductal adenocarcinoma through Drosophila phenotypic screening
|
Sonoshita, M.
|
|
|
211 |
S1 |
p.
|
artikel
|
| 251 |
445 (PB433): Identifying Disease Relevant Macrophage Subtypes in vitro using RNASequencing Transcriptome Profiling
|
Gurney, M.
|
|
|
211 |
S1 |
p.
|
artikel
|
| 252 |
232 (PB220): Identifying drug combinations targeting Claudin-1 for colorectal cancer
|
Rashid, M.
|
|
|
211 |
S1 |
p.
|
artikel
|
| 253 |
452 (PB440): Identifying Regulators of MHC Repression and therapeutic targets to overcome immune evasion in SCLC
|
Sen, T.
|
|
|
211 |
S1 |
p.
|
artikel
|
| 254 |
378 (PB366): Identifying the FXR agonist, obeticholic acid, as a c-SRC modulator to enhance trastuzumab efficacy in HER2 positive breast cancer
|
Attia, Y.
|
|
|
211 |
S1 |
p.
|
artikel
|
| 255 |
377 (PB365): Identifying the genes/proteins that trigger resistance to targeted and IO drugs
|
Waterman-Smith, J.
|
|
|
211 |
S1 |
p.
|
artikel
|
| 256 |
433 (PB421): IFNγ-JAK1-STAT1 Signaling Represses FOXA1 and Drives a Basal-Squamous Transcriptional State in Bladder Cancer
|
Lawrence, S.
|
|
|
211 |
S1 |
p.
|
artikel
|
| 257 |
176 (PB164): IKS012, a novel ADC design with favorable efficacy and safety for treatment of Folate Receptor Alpha-positive cancers
|
Lodge, A.
|
|
|
211 |
S1 |
p.
|
artikel
|
| 258 |
161 (PB149): Immune landscape and CLEVER-1 expression in hepatoblastoma
|
Väyrynen, V.
|
|
|
211 |
S1 |
p.
|
artikel
|
| 259 |
158 (PB146): Immune Monitoring in Preclinical Tumor Mouse Models Using Spectral Analyzer Technology
|
Hummel, J.
|
|
|
211 |
S1 |
p.
|
artikel
|
| 260 |
282 (PB270): Impact of Implant Location on In Vivo Therapeutic Response and Immune Modulation in the MC38-luc Mouse Colon Carcinoma Model
|
Pandey, P.
|
|
|
211 |
S1 |
p.
|
artikel
|
| 261 |
447 (PB435): Implementation and Validation of an Innovative Platform to Discover Monoclonal Antibodies Targeting Tumor-Associated Carbohydrate Antigens (TACAs) for Cancer Immunotherapy
|
Moreira, G.
|
|
|
211 |
S1 |
p.
|
artikel
|
| 262 |
30 (PB018): Improved BRAF/MEK inhibitor efficacy in melanoma using a high-fat diet in male mice
|
Arabi, S.
|
|
|
211 |
S1 |
p.
|
artikel
|
| 263 |
467 (PB455): IND.241: A Canadian Cancer Trials Group liquid-biopsy informed platform trial to evaluate treatment in CDK4/6-inhibitor resistant ER +/HER2- metastatic breast cancer
|
Cosci, C.
|
|
|
211 |
S1 |
p.
|
artikel
|
| 264 |
235 (PB223): IND.243: a multiple expansion cohort, signal seeking and dose confirmation phase 2 trial of the PKMYT1 inhibitor lunresertib
|
Drew, Y.
|
|
|
211 |
S1 |
p.
|
artikel
|
| 265 |
57 (PB045): Individualised schedule optimisation improves rates and severity of anaemia in patients (pts) treated with lunresertib (lunre), a PKMYT1 inhibitor, and camonsertib (cam), an ATR inhibitor, in the phase I MYTHIC study (NCT0485565)
|
Hojgaard, M.
|
|
|
211 |
S1 |
p.
|
artikel
|
| 266 |
199 (PB187): Informative censoring in the TARGET – TP trial evaluating biomarkerdriven thromboprophylaxis
|
Peretz, S. Gabizon
|
|
|
211 |
S1 |
p.
|
artikel
|
| 267 |
311 (PB299): Inhibition of mitophagy hinders the polarization of macrophages towards a M2-like phenotype in pancreatic cancer
|
Wang, H.C.
|
|
|
211 |
S1 |
p.
|
artikel
|
| 268 |
326 (PB314): Integrative Exploration of a Candidate Oncogene in Chromosome 1q Region for Breast Cancer
|
Turan, G.
|
|
|
211 |
S1 |
p.
|
artikel
|
| 269 |
375 (PB363): Investigating cell-cell communication in glioblastoma: implications for radiotherapy resistance and therapeutic strategies
|
Mohand, F.E. Ait
|
|
|
211 |
S1 |
p.
|
artikel
|
| 270 |
458 (PB446): Investigating therapeutic strategies to promote immune rejection of KRASG12C inhibitor-resistant subpopulations in lung cancer
|
Tomaschko, M.
|
|
|
211 |
S1 |
p.
|
artikel
|
| 271 |
37 (PB025): Investigating the Therapeutic Potential of novel STK17A Inhibitor UMF814A in Glioblastoma
|
Castro, J.
|
|
|
211 |
S1 |
p.
|
artikel
|
| 272 |
115 (PB103): Investigation of cabozantinib and zanzalintinib differentiation via in vitro kinase profiling and in vivo tissue and tumor distribution
|
Chang, J.
|
|
|
211 |
S1 |
p.
|
artikel
|
| 273 |
250 (PB238): In Vivo Pharmacokinetics, Pharmacodynamics and Anti-tumour Efficacy of EXS74539: A Novel, Reversible LSD1 Inhibitor for Acute Myeloid Leukaemia
|
Okumura, R.
|
|
|
211 |
S1 |
p.
|
artikel
|
| 274 |
257 (PB245): IOMX-0675, a cross-specific antibody selectively inhibiting LILRB1 and LILRB2, repolarizes immunosuppressive myeloid cells and activates T cells
|
Heinig, K.
|
|
|
211 |
S1 |
p.
|
artikel
|
| 275 |
288 (PB276): Ivermectin enhances the efficacy of modulated electro-hyperthermia in a triple-negative breast cancer mouse model
|
Aloss, K.
|
|
|
211 |
S1 |
p.
|
artikel
|
| 276 |
144 (PB132): JNJ-79032421 is a novel membrane restricted mesothelin targeting Tcell engaging bispecific antibody for treatment of mesothelin-positive cancers
|
Smans, K.
|
|
|
211 |
S1 |
p.
|
artikel
|
| 277 |
396 (PB384): KAT6A inhibitor screening cascade to facilitate novel drug discovery
|
Bing, T.
|
|
|
211 |
S1 |
p.
|
artikel
|
| 278 |
388 (PB376): KO-2806, a next-generation farnesyl transferase inhibitor, re-sensitizes KRAS G12C NSCLC tumors to KRAS G12C mutant-specific inhibitors through mTOR signaling inhibition
|
Patel, H.
|
|
|
211 |
S1 |
p.
|
artikel
|
| 279 |
210 (PB198): KRASmulti inhibition and checkpoint targeting therapy show strong combination potential in KRAS wild-type and KRASG12V-driven syngeneic mouse models of pancreatic cancer
|
Ebner, F.
|
|
|
211 |
S1 |
p.
|
artikel
|
| 280 |
100 (PB088): KRASmulti inhibitor BI 3706674 shows efficacy in KRAS-driven preclinical models of cancer that supports clinical testing in patients with tumors harboring KRASG12V mutations and KRAS wild-type amplifications.
|
Tedeschi, A.
|
|
|
211 |
S1 |
p.
|
artikel
|
| 281 |
239 (PB227): KRAS pharmacological blockade elicits tumoral homologous recombination deficiency exploitable with PARP inhibitors
|
Welch, C.
|
|
|
211 |
S1 |
p.
|
artikel
|
| 282 |
205 (PB193): Landscape of Next Generation Sequencing (NGS)-based Minimal Residual Disease (MRD) assays for Multiple Myeloma (MM) in China
|
Shen, S.
|
|
|
211 |
S1 |
p.
|
artikel
|
| 283 |
169 (PB157): Large-Scale ADC Efficacy Testing in an Organoid Drug Screening Platform Highlights the Need for Functional Assays to Predict Tumor Sensitivity
|
Del Angel Zuvirie, C.
|
|
|
211 |
S1 |
p.
|
artikel
|
| 284 |
429 (PB417): Lessons learned from a pan-cancer exploratory Liquid Biopsy (LB) profiling: the PREICO-LB project
|
Hierro, C.
|
|
|
211 |
S1 |
p.
|
artikel
|
| 285 |
87 (PB075): Lipid metabolism and synthesis pathway analysis of Sigma-2 Receptor and Progesterone Receptor Membrane Component 1 to develop novel cancer cell therapeutics
|
Riad, A.
|
|
|
211 |
S1 |
p.
|
artikel
|
| 286 |
299 (PB287): Lomitapide enhances cytotoxic effects of temozolomide in chemoresistant glioblastoma
|
Ivanova, A.
|
|
|
211 |
S1 |
p.
|
artikel
|
| 287 |
18 (PB006): Long pentraxin 3 (PTX3) as a regulator of lymphangiogenesis and lymphogenous dissemination in melanoma
|
Turati, M.
|
|
|
211 |
S1 |
p.
|
artikel
|
| 288 |
258 (PB246): Loss of DUSP6 Upregulates PD-L1 on Extracellular Vesicles
|
Kim, H.S.
|
|
|
211 |
S1 |
p.
|
artikel
|
| 289 |
33 (PB021): Loss-of-function and gain-of-function genetic screens identify potential biomarkers and combination partners for the highly selective allosteric PI3Kδ inhibitor roginolisib (IOA-244)
|
Tarantelli, C.
|
|
|
211 |
S1 |
p.
|
artikel
|
| 290 |
43 (PB031): MBT-C101, a first-in-class, selective, and potent HSP90 chaperonemediated degrader of PI3Ka
|
Choi, H.S.
|
|
|
211 |
S1 |
p.
|
artikel
|
| 291 |
152 (PB140): MC339, a novel radiopharmaceutical, targets DLL3-expressing cancers of different tissue origins
|
Weng, Z.
|
|
|
211 |
S1 |
p.
|
artikel
|
| 292 |
227 (PB215): Menin inhibitor ziftomenib synergizes with imatinib in tyrosine kinase inhibitor (TKI)-resistant gastrointestinal stromal tumor models
|
Mccloskey, A.
|
|
|
211 |
S1 |
p.
|
artikel
|
| 293 |
170 (PB158): Mesothelin-targeted nanobody-drug conjugates to treat pancreatic cancer
|
Dutta, N.
|
|
|
211 |
S1 |
p.
|
artikel
|
| 294 |
395 (PB383): METTL3 inhibitors screening cascade for new drug discovery
|
Bing, T.
|
|
|
211 |
S1 |
p.
|
artikel
|
| 295 |
80 (PB068): Microtubule affinity-regulating kinases (MARKs) can be a therapeutic target for head and neck squamous cell carcinoma
|
Oh, S.
|
|
|
211 |
S1 |
p.
|
artikel
|
| 296 |
135 (PB123): MITOPE: Phase 2 evaluation of RSO-021, a novel mitochondrial PRX3 inhibitor, as a monotherapy and in combination with paclitaxel in patients with malignant pleural effusion due to mesothelioma or other advanced solid tumors
|
Naumov, G.
|
|
|
211 |
S1 |
p.
|
artikel
|
| 297 |
290 (PB278): Modulating immune response in cholangiocarcinoma: targeting sulfatase-2 for therapeutic intervention
|
Brooks, T.
|
|
|
211 |
S1 |
p.
|
artikel
|
| 298 |
50 (PB038): Modulatory profiling reveals cancer cell-selective dependency on glutamate-cysteine ligase independent of ferroptosis induction
|
Fujihara, K.
|
|
|
211 |
S1 |
p.
|
artikel
|
| 299 |
270 (PB258): Molecular and pharmacological profiling of a prostate cancer PDX panel and in vitro cellular counterparts to identify resistance mechanisms and new therapeutic options
|
Indersie, E.
|
|
|
211 |
S1 |
p.
|
artikel
|
| 300 |
203 (PB191): Molecular biomarker testing in Slovenian non-small cell lung cancer patients in early and late stages of the disease
|
Mohorcic, K.
|
|
|
211 |
S1 |
p.
|
artikel
|
| 301 |
424 (PB412): Molecular drivers of plasticity and immunosuppression in a single-cell RNA sequencing and multicolor image analysis of human small-cell lung cancer
|
Sen, T.
|
|
|
211 |
S1 |
p.
|
artikel
|
| 302 |
47 (PB035): MOMA-313 is a potent, selective Polθ inhibitor that enhances response to PARP inhibition in HR-deficient tumor models
|
Evans, E.
|
|
|
211 |
S1 |
p.
|
artikel
|
| 303 |
213 (PB201): MYC Inhibition by OMO-103 Reprograms Tumor Immunity and Enhances Immunotherapy Efficacy in KRAS Mutant NSCLC
|
Serra, S. Casacuberta
|
|
|
211 |
S1 |
p.
|
artikel
|
| 304 |
469 (PB457): Nanoparticle-induced virus immune tolerance during oncolytic therapy of gliomas
|
Shin, D.H.
|
|
|
211 |
S1 |
p.
|
artikel
|
| 305 |
367 (PB355): NanoSyrinx: Specific delivery of complex active biologics into target cells using nanosyringe drug delivery technology
|
Titimeaua, A.
|
|
|
211 |
S1 |
p.
|
artikel
|
| 306 |
453 (PB441): NCI/CTEP #10276: A Phase I/II Study of Peposertib and Avelumab in Combination with Hypofractionated Radiation in Patients with Advanced/Metastatic Solid Tumors and Hepatobiliary Malignancies
|
Spencer, K.
|
|
|
211 |
S1 |
p.
|
artikel
|
| 307 |
359 (PB347): Neoplastic small extracellular vesicles cause DNA damage and inhibit DNA damage repair in Barrett’s esophagus cells: A model for synthetic lethality by PARP inhibitors
|
Zhang, Q.
|
|
|
211 |
S1 |
p.
|
artikel
|
| 308 |
123 (PB111): New dual-pharmacophore dinucleotide prodrugs as potent telomere targeting anticancer molecules
|
Mender, I.
|
|
|
211 |
S1 |
p.
|
artikel
|
| 309 |
165 (PB153): NEXUS-01, a phase 1 study of LY4052031, an antibody-drug conjugate targeting Nectin-4 in participants with advanced or metastatic urothelial carcinoma or other solid tumors (Trial in Progress)
|
Baldini, C.
|
|
|
211 |
S1 |
p.
|
artikel
|
| 310 |
131 (PB119): Novel Androgen Receptor Antagonists with Improved Activity Against Common LBD Variants Associated with Therapeutic Resistance
|
Malik, R.
|
|
|
211 |
S1 |
p.
|
artikel
|
| 311 |
380 (PB368): Novel casein kinase 1 alpha inhibitors for the treatment of resistant AML and solid tumors
|
Janovská, P.
|
|
|
211 |
S1 |
p.
|
artikel
|
| 312 |
371 (PB359): Novel compounds for targeting Protein-Protein interactions in TRF1 and TRF2
|
Krzemieniecki, R.
|
|
|
211 |
S1 |
p.
|
artikel
|
| 313 |
188 (PB176): Novel HSP90 inhibitors SP15 and SP11: Promoting intrinsic apoptotic pathway and immune activation in cancer cells
|
MV, S.
|
|
|
211 |
S1 |
p.
|
artikel
|
| 314 |
191 (PB179): Novel strategy to improve response of high risk HPV+ HNSCC to radiation therapy
|
Vemulamanda, S.
|
|
|
211 |
S1 |
p.
|
artikel
|
| 315 |
209 (PB197): Novel tumor microenvironment ameliorator E7130 shows substantial combination efficacy with enzalutamide in a preclinical model of castration-resistant prostate cancer.
|
Abe, T.
|
|
|
211 |
S1 |
p.
|
artikel
|
| 316 |
226 (PB214): NRF2 disruption by rocaglate translation inhibitors sensitizes tumors to induction of ferroptosis and killing by CAR-T cells
|
Manara, P.
|
|
|
211 |
S1 |
p.
|
artikel
|
| 317 |
292 (PB280): NTRK mRNA overexpression is common in human tumors and associates with sensitivity to entrectinib in cell line models
|
de Oliveira Cavagna, R.
|
|
|
211 |
S1 |
p.
|
artikel
|
| 318 |
238 (PB226): NXP900, a novel YES1/SRC Kinase Inhibitor in Phase 1 Dose Escalation, Demonstrates Potent Synergy with ALK Inhibitors in ALK Resistant Cell Lines
|
Unciti-Broceta, A.
|
|
|
211 |
S1 |
p.
|
artikel
|
| 319 |
88 (PB076): Obesity reveals potential therapeutic targets in adipocyte- derived extracellular vesicles of gastric cancer patients
|
Rubin, A.
|
|
|
211 |
S1 |
p.
|
artikel
|
| 320 |
306 (PB294): OMX-0407 a spectrum selective kinase inhibitor shows preclinical and clinical efficacy in Angiosarcoma, an indication of high unmet medical need
|
Maser, I.P.
|
|
|
211 |
S1 |
p.
|
artikel
|
| 321 |
247 (PB235): Oncogenic human papillomavirus hijacks p300 to drive viral transcription, creating a therapeutic vulnerability that can be exploited with selective p300/CBP catalytic inhibitors
|
Kobylarz, M.
|
|
|
211 |
S1 |
p.
|
artikel
|
| 322 |
460 (PB448): On-target – prioritizing specificity during T Cell Engager discovery against peptide: HLA antigens
|
Turley, J.
|
|
|
211 |
S1 |
p.
|
artikel
|
| 323 |
347 (PB335): Optimized Ku-DNA binding inhibitors impact the cellular and in vivo DNA damage response to DSB-inducing therapies
|
Mendoza-Munoz, P.
|
|
|
211 |
S1 |
p.
|
artikel
|
| 324 |
179 (PB167): Optimizing Ex Vivo Assays: The Crucial Step for Advancing ADCs to Clinical Success
|
Sánchez, J.
|
|
|
211 |
S1 |
p.
|
artikel
|
| 325 |
410 (PB398): Optimizing metastatic tumor therapies: innovative drug screening using colonies derived from circulating tumor cells
|
Shih, S.J.
|
|
|
211 |
S1 |
p.
|
artikel
|
| 326 |
231 (PB219): Optimizing treatment strategies for HER2-positive breast and gastric cancer: preclinical evaluation of disitamab vedotin, trastuzumab emtansine, trastuzumab deruxtecan, and their combinations therapies in mouse models
|
Pourjamal, N.
|
|
|
211 |
S1 |
p.
|
artikel
|
| 327 |
62 (PB050): ORIC-114, a highly selective, brain penetrant EGFR and HER2 inhibitor, demonstrates best-in-class properties against Exon 20 insertions and other atypical EGFR mutations
|
Junttila, M.
|
|
|
211 |
S1 |
p.
|
artikel
|
| 328 |
275 (PB263): Osimertinib resistant NSCLC Patient derived xenograft model mimic clinical response status of multiple TKI treatments in preclinical study
|
Jinxi, W.
|
|
|
211 |
S1 |
p.
|
artikel
|
| 329 |
334 (PB322): PARP1 inhibitor resistant cell line generation and DDR cell panel development
|
Bing, T.
|
|
|
211 |
S1 |
p.
|
artikel
|
| 330 |
53 (PB041): PARP-targeted theranostic radiopharmaceutical therapy for drugresistant ovarian cancer
|
Gitto, S.
|
|
|
211 |
S1 |
p.
|
artikel
|
| 331 |
178 (PB166): Patient-derived models of ER+ HER2 - metastatic breast cancers reveal KRAS-MAPK signalling pathway as therapeutic target for overcoming resistance to trastuzumab-deruxtecan
|
Marangoni, E.
|
|
|
211 |
S1 |
p.
|
artikel
|
| 332 |
276 (PB264): Patient-derived tissue specimen in target evaluation – possibilities and limitations
|
Kallendrusch, S.
|
|
|
211 |
S1 |
p.
|
artikel
|
| 333 |
273 (PB261): PD-1 inhibition in patient-derived tissue cultures (PDTC) of gastric cancer
|
Hoang, N.A.
|
|
|
211 |
S1 |
p.
|
artikel
|
| 334 |
260 (PB248): PD-L1 PET/CT imaging shows partial tumor saturation during atezolizumab treatment
|
Smit, L.M.
|
|
|
211 |
S1 |
p.
|
artikel
|
| 335 |
117 (PB105): Peroxiredoxin 3 (PRX3) – a new target for the treatment of aggressive cancers.
|
Gibson, V.
|
|
|
211 |
S1 |
p.
|
artikel
|
| 336 |
435 (PB423): Persistence of BRCA1 and RAD51C methylation after neoadjuvant chemotherapy in high risk TNBC
|
Pettitt, S.
|
|
|
211 |
S1 |
p.
|
artikel
|
| 337 |
132 (PB120): Pharmacokinetic and pharmacodynamic analyses of OMO-103 in preclinical and patient tissues
|
Martín, S. Martínez
|
|
|
211 |
S1 |
p.
|
artikel
|
| 338 |
102 (PB090): Pharmacological characterization and improved PK of new small protein-protein-interaction inhibitors targeting the Eph-ephrin system
|
Giorgio, C.
|
|
|
211 |
S1 |
p.
|
artikel
|
| 339 |
128 (PB116): Pharmacological Targeting of Mitochondrial Quality Control Pathways Leads to Tumor Growth Inhibition in Solid Tumors
|
Kostura, M.
|
|
|
211 |
S1 |
p.
|
artikel
|
| 340 |
244 (PB232): Pharmacologic inhibition of YTHDC1 biomolecular condensates as a novel approach to targeting L-MYC driven small cell lung cancer
|
Centore, R.
|
|
|
211 |
S1 |
p.
|
artikel
|
| 341 |
70 (PB058): Phase 1/2 clinical trial of JIN-A02, a 4th generation EGFR-tyrosine kinase inhibitor (TKI), in patients with 3rd generation EGFR-TKI resistance in EGFR mutated advanced/metastatic non-small cell lung cancer (NSCLC)
|
Lim, S.M.
|
|
|
211 |
S1 |
p.
|
artikel
|
| 342 |
256 (PB244): Phase 1 clinical trial of the anti-LLT1 antibody ZM008 as monotherapy and in combination with pembrolizumab in advanced solid tumor patients
|
Ghosh, M.
|
|
|
211 |
S1 |
p.
|
artikel
|
| 343 |
34 (PB022): Phase I/II trial of RVU120, a CDK8/CDK19 inhibitor in patients with relapsed/refractory metastatic or advanced solid tumors
|
Jedrzejewski, J.
|
|
|
211 |
S1 |
p.
|
artikel
|
| 344 |
223 (PB211): PHI-101 synergizes with chemotherapy and PARP inhibitors in preclinical models of ovarian cancer
|
Sung, G.J.
|
|
|
211 |
S1 |
p.
|
artikel
|
| 345 |
337 (PB325): Poly(ADP-Ribose) Polymerase (PARP) inhibition in metastatic breast cancer: comparison of therapeutic outcomes between patients with BRCA1/2 mutations and other alterations
|
Coleman, N.
|
|
|
211 |
S1 |
p.
|
artikel
|
| 346 |
438 (PB426): Precision-guided treatment improves outcomes for children with highrisk cancers
|
Lau, L.
|
|
|
211 |
S1 |
p.
|
artikel
|
| 347 |
355 (PB343): Preclinical Candidate SYN608 - a Novel PARG Inhibitor with Excellent Anti-tumor Activity
|
Shi, S.
|
|
|
211 |
S1 |
p.
|
artikel
|
| 348 |
41 (PB029): Preclinical characterization of ABSK131, a potential best-in-class MTAcooperative PRMT5 inhibitor
|
Pan, W.
|
|
|
211 |
S1 |
p.
|
artikel
|
| 349 |
145 (PB133): Preclinical characterization of a novel PI3Kα H1047R mutant-selective inhibitor
|
Smith, A.C.
|
|
|
211 |
S1 |
p.
|
artikel
|
| 350 |
124 (PB112): Preclinical characterization of a Selective FGFR2/3 inhibitor, GSC000829
|
Han, T.
|
|
|
211 |
S1 |
p.
|
artikel
|
| 351 |
142 (PB130): Preclinical characterization of HD10019, a FLT3 kinase inhibitor with optimized polypharmacology to treat FLT3-mutant AML
|
Shah, N.
|
|
|
211 |
S1 |
p.
|
artikel
|
| 352 |
171 (PB159): Preclinical characterization of NaPi2b-PL2202, a novel exatecan-based antibody drug conjugate
|
Jabeen, A.
|
|
|
211 |
S1 |
p.
|
artikel
|
| 353 |
356 (PB344): Preclinical characterization of NTX-452, a potent, selective and highly efficacious WRN inhibitor for the treatment of MSI-H tumors
|
Boiko, S.
|
|
|
211 |
S1 |
p.
|
artikel
|
| 354 |
116 (PB104): Preclinical characterization of SKY-1214, a small molecule splicing modulator of Fanconi Anemia pathway members for the treatment of multiple myeloma and non-Hodgkin’s lymphoma
|
Rauch, S.
|
|
|
211 |
S1 |
p.
|
artikel
|
| 355 |
83 (PB071): Preclinical characterization of SMARCA2-selective monovalent direct degraders
|
Parker, G.
|
|
|
211 |
S1 |
p.
|
artikel
|
| 356 |
305 (PB293): Preclinical development of PLGA-encapsulated Disulfiram for treatment of malignant mesothelioma
|
Lakshmanan, Y.
|
|
|
211 |
S1 |
p.
|
artikel
|
| 357 |
168 (PB156): Preclinical evaluation of FLT3 biparatopic antibodies for ADC development in AML
|
Catozzi, A.
|
|
|
211 |
S1 |
p.
|
artikel
|
| 358 |
409 (PB397): Preclinical evaluation of hybrid molecules targeting EGFR and DNA on cervical cancer
|
Rosa, M.
|
|
|
211 |
S1 |
p.
|
artikel
|
| 359 |
175 (PB163): Preclinical evaluation of IM-1021, a ROR1-targeted antibody-drug conjugate with a novel topoisomerase I linker payload
|
Lawrence, R.
|
|
|
211 |
S1 |
p.
|
artikel
|
| 360 |
297 (PB285): Preclinical Evaluation of RMC-7977, a Multi-Selective RAS(ON) Inhibitor, as a Therapeutic Strategy for KRAS-Mutant Cholangiocarcinoma
|
Cadierno, R. Entrialgo
|
|
|
211 |
S1 |
p.
|
artikel
|
| 361 |
49 (PB037): Preclinical Evaluation of the Antitumor Activity and Toxicity of New Phosphoinositide 3-kinases Inhibitors
|
Peixoto, M.C. Fonseca
|
|
|
211 |
S1 |
p.
|
artikel
|
| 362 |
366 (PB354): Preclinical evaluation of TTR-201, a novel ferrous-iron responsive (FIRE) conjugate of the topoisomerase-I inhibitor exatecan
|
Lee, G.
|
|
|
211 |
S1 |
p.
|
artikel
|
| 363 |
295 (PB283): Predictive Markers of Response to the MDM2 Degrader KT-253
|
Dumont, N.
|
|
|
211 |
S1 |
p.
|
artikel
|
| 364 |
143 (PB131): Preliminary Safety and Pharmacokinetics of the MET-TKI DO-2 in Patients with Advanced Solid Tumors Harboring MET Aberrations: A Phase I Study
|
Perera, T.
|
|
|
211 |
S1 |
p.
|
artikel
|
| 365 |
193 (PB181): Preparing for Cancer Foundational models: a study of how LLMs perform in cancer applications
|
Weil, M.
|
|
|
211 |
S1 |
p.
|
artikel
|
| 366 |
346 (PB334): Profiling of PARP1-selective inhibitor DSB2455 in HR deficient and proficient cancer models as monotherapy and in combination
|
Mcguinness, B.
|
|
|
211 |
S1 |
p.
|
artikel
|
| 367 |
321 (PB309): Proteogenomic Characterization Identifies Clinical Subgroups in EGFR and ALK Wild-type Never-smoker Lung Adenocarcinoma
|
Kim, H.
|
|
|
211 |
S1 |
p.
|
artikel
|
| 368 |
289 (PB277): Pulsatile induction of the p53 pathway by MDM2 antagonist ASTX295 shows an enhanced therapeutic index in vivo
|
Fazal, L.
|
|
|
211 |
S1 |
p.
|
artikel
|
| 369 |
208 (PB196): Quantification of PI3K/AKT/mTOR pathway inhibition is predictive of biological response
|
Van Brussel, A.
|
|
|
211 |
S1 |
p.
|
artikel
|
| 370 |
332 (PB320): Radiotherapy improves efficacy of the PARP inhibitor Niraparib in a preclinical model of triple negative breast cancer
|
Binder, P.
|
|
|
211 |
S1 |
p.
|
artikel
|
| 371 |
234 (PB222): Rational combination of pan-TEAD inhibitor SW-682 and MEK inhibitor mirdametinib in head and neck squamous cell carcinomas leads to synergistic response
|
Schirmer, A.
|
|
|
211 |
S1 |
p.
|
artikel
|
| 372 |
330 (PB318): Rational design of a superior single agent active, potential best-in-class WEE1/PKMYT1 inhibitor using Acrivon Predictive Precision Proteomics (AP3)
|
Baddour-Sousounis, J.
|
|
|
211 |
S1 |
p.
|
artikel
|
| 373 |
385 (PB373): Relative levels of IQGAP1 and IQGAP2: Modulator of stemness, resistance and relapse dynamics in breast cancer
|
Mohapatra, T.
|
|
|
211 |
S1 |
p.
|
artikel
|
| 374 |
68 (PB056): REM-422, a potent, selective, oral small moleculemRNA degrader of the MYB oncogene, induces regressions in mouse patient-derived xenograft models of adenoid cystic carcinoma
|
Cameron, M.
|
|
|
211 |
S1 |
p.
|
artikel
|
| 375 |
342 (PB330): Replication protein A inhibitors abrogate ATR kinase signaling and disrupt replication fork dynamics
|
Jordan, M.
|
|
|
211 |
S1 |
p.
|
artikel
|
| 376 |
407 (PB395): Residence time of DO-2, a novel deuterated MET kinase inhibitor on the endogenous target: Differentiates DO-2 from competitor agents
|
Perera, T.
|
|
|
211 |
S1 |
p.
|
artikel
|
| 377 |
403 (PB391): Response of canine and human osteosarcoma cell lines to targeted agents compared to clinically relevant exposure
|
Gustafson, D.
|
|
|
211 |
S1 |
p.
|
artikel
|
| 378 |
111 (PB099): Response of canine osteosarcoma cell lines to inhibition of the class III PI-3 kinase VPS34
|
Leverett, J.
|
|
|
211 |
S1 |
p.
|
artikel
|
| 379 |
280 (PB268): Response to precision-guided treatments in patient-derived models of metastatic breast cancer
|
Montaudon, E.
|
|
|
211 |
S1 |
p.
|
artikel
|
| 380 |
182 (PB170): Results from a phase 1/2, first-in-human, dose escalation and dose expansion study of an investigational anti-ADAM9 antibody-drug conjugate IMGC936 in patients with advanced solid tumors
|
Subbiah, V.
|
|
|
211 |
S1 |
p.
|
artikel
|
| 381 |
285 (PB273): RET overexpression in absence of fusions or mutations associates with sensitivity to RET TKIs in lung cancer
|
Sullivan, I.
|
|
|
211 |
S1 |
p.
|
artikel
|
| 382 |
465 (PB453): RGT-264 a highly potent, selective and orally bioavailable HPK1 (MAP4K1) inhibitor augments immune activation and anti-tumor immunity
|
Xiao, F.
|
|
|
211 |
S1 |
p.
|
artikel
|
| 383 |
353 (PB341): R-loop-induced DNA damage as a therapeutic strategy for ER+ breast cancer
|
Roberts, A.
|
|
|
211 |
S1 |
p.
|
artikel
|
| 384 |
278 (PB266): ROS1 mRNA upregulation is common in human tumors and associates with sensitivity to tyrosine kinase inhibitors in cell line models
|
Molina-Vila, M.
|
|
|
211 |
S1 |
p.
|
artikel
|
| 385 |
24 (PB012): Runx1t1 is an epigenetic regulator essential for MYCN-driven neuroblastoma tumorigenesis
|
Norris, M.
|
|
|
211 |
S1 |
p.
|
artikel
|
| 386 |
77 (PB065): Safety and Preliminary Efficacy of APR-1051, a WEE1 Inhibitor, in a Phase 1 Study of Patients with Cancer-Associated Gene Alterations (ACESOT-1051)
|
Yap, T.A.
|
|
|
211 |
S1 |
p.
|
artikel
|
| 387 |
23 (PB011): scRNA-seq and single-cell spatial transcriptome of diffuse-type gastric cancer mouse model reveals a novel interaction between neutrophils and cancer cells
|
Kakiuchi, M.
|
|
|
211 |
S1 |
p.
|
artikel
|
| 388 |
92 (PB080): Selective Inhibition of Active KRASG13C with RMC-8839 Reveals an Increased Dependence of Codon-13 KRAS-Mutant Cancers on Wild- Type RAS Isoforms
|
Seamon, K.
|
|
|
211 |
S1 |
p.
|
artikel
|
| 389 |
389 (PB377): Sensitization to carboplatin chemotherapy by decoding intra tumor heterogeneity in triple negative breast cancer
|
Chowdhury, S. Roy
|
|
|
211 |
S1 |
p.
|
artikel
|
| 390 |
418 (PB406): Single nucleotide polymorphisms in microRNA genes associate with the risk of Oral Squamous Cell Carcinoma in Central Indian Population
|
Kumar, A.
|
|
|
211 |
S1 |
p.
|
artikel
|
| 391 |
343 (PB331): SLX4 and XPF in cancer and cancer treatments
|
Emeline, C.P.
|
|
|
211 |
S1 |
p.
|
artikel
|
| 392 |
338 (PB326): Small-molecule bifunctional inhibitors of PARP1/2 and HDAC enzymes
|
Truong, S.
|
|
|
211 |
S1 |
p.
|
artikel
|
| 393 |
351 (PB339): Small molecule disruptor of RAD51:BRCA2 interaction reduces nuclear RAD51 foci and is efficacious in ovarian cancer pre-clinical model
|
Patra, S.
|
|
|
211 |
S1 |
p.
|
artikel
|
| 394 |
204 (PB192): Spatial Analysis of Tumor-Infiltrating Lymphocytes in mRCC Patients Treated with Pexa-Vec (Thymidine Kinase-Deactivated Vaccinia Virus plus GM-CSF) and cemiplimab (REGN2810; Anti-PD-1)
|
Rha, S.Y.
|
|
|
211 |
S1 |
p.
|
artikel
|
| 395 |
271 (PB259): Spry1 silencing reduces HIF1α-induced glycolysis and impairs angiogenesis in BRAF-mutant cutaneous melanoma
|
Montico, B.
|
|
|
211 |
S1 |
p.
|
artikel
|
| 396 |
360 (PB348): Squalene nanoparticles prevent non-alcoholic steatohepatitis through antioxidant features by targeting TXNDC5
|
Bidooki, S.H.
|
|
|
211 |
S1 |
p.
|
artikel
|
| 397 |
195 (PB183): STRIDE™: Quantitative DNA damage detection method to replace limitations of γH2AX assay
|
Bialecka, M.
|
|
|
211 |
S1 |
p.
|
artikel
|
| 398 |
350 (PB338): Structural variants of BRCA1/2 represent a novel biomarker of homologous recombination deficiency in multiple tumour types
|
Oswald, A.
|
|
|
211 |
S1 |
p.
|
artikel
|
| 399 |
294 (PB282): Suppression of Glioblastoma Progression by FDA-Approved Central Nervous System-Accumulating Drugs via Autophagy Modulation and ER Stress-Induced Apoptosis
|
Dey, S.
|
|
|
211 |
S1 |
p.
|
artikel
|
| 400 |
127 (PB115): Survival benefit and tumor regression with a dual RAS/β-catenin inhibitor, ADT-030, in murine models of pancreatic and lung cancer
|
Bandi, D.S.R.
|
|
|
211 |
S1 |
p.
|
artikel
|
| 401 |
310 (PB298): Synergistic Anti-Tumor Effects of the Novel HDAC Inhibitor, ABT-301, with Immune Checkpoint Inhibitors in Colorectal Cancer Through Regulation of Immune Response and Anti-Angiogenesis
|
Tan, K.T.
|
|
|
211 |
S1 |
p.
|
artikel
|
| 402 |
66 (PB054): Synergistic effect of JIN-001, a novel HPS90 selective inhibitor, with platinum or paclitaxel on multi-resistant ovarian cancer
|
Kim, J.
|
|
|
211 |
S1 |
p.
|
artikel
|
| 403 |
225 (PB213): Synergistic enhancement of KRASG12C inhibitor adagrasib by AMD1 inhibitor SAM486 in non-small cell lung cancer: in vitro and in vivo studies
|
Lopez-Muñoz, R.
|
|
|
211 |
S1 |
p.
|
artikel
|
| 404 |
344 (PB332): Systematic assessment of ALC1 depletion as a therapeutic approach in homologous recombination deficient cells
|
Llorca-Cardenosa, M.
|
|
|
211 |
S1 |
p.
|
artikel
|
| 405 |
56 (PB044): Systemic Targeted Therapies in Patients with Relapsed/Refractory Advanced Stage Cutaneous T-cell Lymphoma: A Real-World Single- Centre Case Series
|
Hedebo, S.
|
|
|
211 |
S1 |
p.
|
artikel
|
| 406 |
206 (PB194): Tailoring the Diagnostic Pathway in Patients with Gastric Cancer (GC) Using the Innovative inPROBE® Technology Platform to Assess HER2 Expression in Peritoneal Lavage: A Pilot Study
|
Stencel, D.
|
|
|
211 |
S1 |
p.
|
artikel
|
| 407 |
252 (PB240): Targeted CRISPR-Knockout (KO) screening to identify FOXF1 regulators and therapeutic strategies in Gastrointestinal stromal tumor (GIST)
|
Tomas, F.
|
|
|
211 |
S1 |
p.
|
artikel
|
| 408 |
27 (PB015): Targeted degradation of NTAQ1 using a CRBN molecular glue to study the N-degron pathway
|
Abuhammad, S.
|
|
|
211 |
S1 |
p.
|
artikel
|
| 409 |
160 (PB148): Targeting AXL kinase with Bemcentinib to enhance Type 1 IFN response and sensitize tumors to chemo-immunotherapy
|
Siraji, M.I.
|
|
|
211 |
S1 |
p.
|
artikel
|
| 410 |
108 (PB096): Targeting brain metastasis from triple-negative breast cancer by blocking CSF1R signaling in the tumor microenvironment
|
Zhang, W.
|
|
|
211 |
S1 |
p.
|
artikel
|
| 411 |
365 (PB353): Targeting fibroblast activation protein to improve immunotherapy efficacy in head and neck squamous cell carcinoma
|
Grisham, C.
|
|
|
211 |
S1 |
p.
|
artikel
|
| 412 |
298 (PB286): Targeting GPR89 as a novel therapeutic strategy for breast cancer
|
Ferro, R.
|
|
|
211 |
S1 |
p.
|
artikel
|
| 413 |
439 (PB427): Targeting Ion Channel LRRC8A to Open the Blood-Tumor Barrier for Treating Brain Cancer
|
Bahrampour, S.
|
|
|
211 |
S1 |
p.
|
artikel
|
| 414 |
113 (PB101): Targeting KRAS codon 13 mutations using direct combination approaches in non-small cell lung cancer
|
Adderley, H.
|
|
|
211 |
S1 |
p.
|
artikel
|
| 415 |
237 (PB225): Targeting NOS sensitizes the NRAS-mutant melanomas to MEK inhibition and induces Immunogenic Cell Death
|
Srivastava, J.
|
|
|
211 |
S1 |
p.
|
artikel
|
| 416 |
316 (PB304): Targeting prostein (SLC45A3) and ERG for interception of prostate cancer using self-amplifying RNA vaccines
|
Shoemaker, R.
|
|
|
211 |
S1 |
p.
|
artikel
|
| 417 |
293 (PB281): Targeting site-specific N-glycosylated B7H3 induces potent antitumor immunity
|
Deng, R.
|
|
|
211 |
S1 |
p.
|
artikel
|
| 418 |
376 (PB364): Targeting TGF-β signaling components to ameliorate Palbociclib resistance in breast cancer
|
Ali, M.
|
|
|
211 |
S1 |
p.
|
artikel
|
| 419 |
73 (PB061): Targeting the catalytic HAT domain of CBP/p300 for the treatment of hormone-dependent breast and prostate cancers
|
Hearn, K.
|
|
|
211 |
S1 |
p.
|
artikel
|
| 420 |
105 (PB093): Targeting the CBM signalosome with a MALT1 scaffolding inhibitor for treatment of NFkB driven solid tumors
|
Yao, Y.
|
|
|
211 |
S1 |
p.
|
artikel
|
| 421 |
16 (PB004): Targeting the DNA Damage Response sensor Replication Protein A for first in class cancer therapy
|
Pawelczak, K.
|
|
|
211 |
S1 |
p.
|
artikel
|
| 422 |
64 (PB052): Targeting the Guardians of Telomeres: A New Approach for Anticancer Drug Development
|
Kallingal, A.
|
|
|
211 |
S1 |
p.
|
artikel
|
| 423 |
253 (PB241): Targeting the HuR-RNA complexes as innovative strategy for glioblastoma treatment
|
Bedeschi, M.
|
|
|
211 |
S1 |
p.
|
artikel
|
| 424 |
242 (PB230): Targeting Thymidylate Synthase mRNA regulatory element with a novel family of Berberine derivatives
|
Plasencia, C.
|
|
|
211 |
S1 |
p.
|
artikel
|
| 425 |
60 (PB048): TAS3351, a fourth-generation brain-penetrating EGFR inhibitor designed to target common EGFR mutations, including those with or without T790M and C797S resistance mutations
|
Iwasaki, J.
|
|
|
211 |
S1 |
p.
|
artikel
|
| 426 |
236 (PB224): Tazemetostat and doxorubicin combined treatment in patient-derived preclinical models of epithelioid sarcoma
|
Soffientini, C.
|
|
|
211 |
S1 |
p.
|
artikel
|
| 427 |
39 (PB027): TEAD inhibition by SW-682 potentiates activity of targeted therapies in NSCLC models
|
Chen, L.
|
|
|
211 |
S1 |
p.
|
artikel
|
| 428 |
17 (PB005): The anti-angiogenic multi-kinase inhibitor AL3810 exerts differential effects on tumor infiltrating CD8+ T cell subsets and cooperatively enhances the anti-tumor effects of PD-1 blockade therapy
|
Fang, K.
|
|
|
211 |
S1 |
p.
|
artikel
|
| 429 |
54 (PB042): The Application of Small Molecule ClpP Agonists as Novel Anti-Cancer Agents
|
Graves, L.
|
|
|
211 |
S1 |
p.
|
artikel
|
| 430 |
198 (PB186): The association of CT45 expression with the therapeutic response in ovarian cancer
|
Dubey, H.
|
|
|
211 |
S1 |
p.
|
artikel
|
| 431 |
249 (PB237): The bromodomain and extraterminal domain family proteins, BRD2, BRD3 and BRD4, are enrolled in H19-dependent transcriptional regulation of cell adhesion molecules and modulate metastatic dissemination program in prostate cancer
|
Pecci, V.
|
|
|
211 |
S1 |
p.
|
artikel
|
| 432 |
196 (PB184): The direct evaluation of homologous recombination activity in tissues to predict the risk of hereditary breast and ovarian cancer and the sensitivity to PARP inhibitor
|
Chiba, N.
|
|
|
211 |
S1 |
p.
|
artikel
|
| 433 |
154 (PB142): The discovery of imidazo[4,5-c]pyridine-2-ones as selective inhibitors of DNA-dependent protein kinase and effective radiosensitisers
|
Hay, M.
|
|
|
211 |
S1 |
p.
|
artikel
|
| 434 |
71 (PB059): The efficacy and safety of a selective PARP1 inhibitor ACE-86225106 in patients with advanced solid tumors: preliminary results from a first-inhuman phase 1/2 study
|
Liu, S.
|
|
|
211 |
S1 |
p.
|
artikel
|
| 435 |
394 (PB382): The establishment of AR cell-based and biochemical assays facilitates novel drug discovery in prostate cancer and breast cancer
|
Bing, T.
|
|
|
211 |
S1 |
p.
|
artikel
|
| 436 |
328 (PB316): The Impact of mRNA Degradation on Transcriptome Analysis: A Rapid Algorithm for Calculating a Novel Degradation Index using Sequencing Data
|
Xie, Z.
|
|
|
211 |
S1 |
p.
|
artikel
|
| 437 |
15 (PB003): The IMPROVE framework for automating and standardizing tumor drug response prediction modeling
|
Weil, M.
|
|
|
211 |
S1 |
p.
|
artikel
|
| 438 |
399 (PB387): The In Vivo Hollow Fiber Model: A Valuable Tool for Developing Selective KRas Inhibitors
|
Metzger, P.
|
|
|
211 |
S1 |
p.
|
artikel
|
| 439 |
44 (PB032): The MDM2 degraders KTX-049 and KT-253 are highly active in wild-type TP53 (WT p53) Merkel cell carcinoma (MCC)
|
Chutake, Y.
|
|
|
211 |
S1 |
p.
|
artikel
|
| 440 |
216 (PB204): The mechanistic basis of both deep and durable antitumor activity by combinatorial inhibition of MAT2A and PRMT5 in MTAP-deleted tumors
|
Garbett, D.
|
|
|
211 |
S1 |
p.
|
artikel
|
| 441 |
90 (PB078): The MET inhibitor savolitinib shows anti-tumor activity in a pre-clinical, intracranial, MET dependent, xenograft model
|
Schuller, A.
|
|
|
211 |
S1 |
p.
|
artikel
|
| 442 |
390 (PB378): The next-generation farnesyl transferase inhibitor KO-2806 sensitizes colorectal cancers to pan-RAS inhibition
|
Smith, A.
|
|
|
211 |
S1 |
p.
|
artikel
|
| 443 |
112 (PB100): The novel ATR inhibitor elimusertib is efficacious as monotherapy and in combination with radiation in pdox models of pediatric high-grade glioma
|
Palacios, M. Suarez
|
|
|
211 |
S1 |
p.
|
artikel
|
| 444 |
38 (PB026): The novel dual MEK inhibitor ABM-4095 for RAS-mutated lung cancer as a single agent or in combination with known therapies
|
Chen, C.
|
|
|
211 |
S1 |
p.
|
artikel
|
| 445 |
185 (PB173): The novel peptide drug conjugate AVA6103 is a FAP-enabled preCISION™ medicine which targets Topoisomerase I to the tumor microenvironment via FAP cleavage
|
Watts, E.
|
|
|
211 |
S1 |
p.
|
artikel
|
| 446 |
125 (PB113): The novel potent Pan-TEAD inhibitor, SB6863, inhibits oncogenic YAP1/TAZ-TEAD signaling and exhibits robust tumor regression in preclinical mesothelioma models
|
Lee, O.Y.
|
|
|
211 |
S1 |
p.
|
artikel
|
| 447 |
335 (PB323): The novel WEE1i, APR-1051, does not substantially off-target PLK1, PLK2, or PLK3 and exhibits favorable in vivo characteristics for treating CCNE1-overexpressing cancers
|
Hansbarger, M.
|
|
|
211 |
S1 |
p.
|
artikel
|
| 448 |
217 (PB205): Therapeutic impact and reactivation of tumor immunity by MYC inhibition in KRAS-driven NSCLC with diverse mutational landscapes
|
González-Larreategui, I.
|
|
|
211 |
S1 |
p.
|
artikel
|
| 449 |
233 (PB221): Therapeutic targeting of NRF2 increases sensitivity to chemotherapy in various solid tumors
|
Roy, N.
|
|
|
211 |
S1 |
p.
|
artikel
|
| 450 |
307 (PB295): The RAS(ON) multi-selective inhibitor RMC-6236 synergizes with TCelldirected immunotherapies to extend durability of antitumor activity in preclinical RAS-driven cancer models
|
Menard, M.
|
|
|
211 |
S1 |
p.
|
artikel
|
| 451 |
220 (PB208): The selectiveSMARCA2 degrader, PRT3789, counteracts the protective cellular stress response to chemotherapy and enhances the efficacy of standard of care chemotherapeutic agents in SMARCA4 mutant NSCLC models
|
Hulse, M.
|
|
|
211 |
S1 |
p.
|
artikel
|
| 452 |
19 (PB007): The SRG Rat, an immunodeficient model for orthotopic glioblastoma, diffuse intrinsic pontine glioma (DIPG) PDX, and intracranial metastatic breast cancer PDX tumors
|
Begemann, D.
|
|
|
211 |
S1 |
p.
|
artikel
|
| 453 |
93 (PB081): The T-BOX transcription factors TBX2 and TBX3 are molecular targets of piroctone olamine in the treatment of pancreatic ductal adenocarcinoma
|
Serala, K.
|
|
|
211 |
S1 |
p.
|
artikel
|
| 454 |
74 (PB062): The transcriptional regulation of TBX3 by the c-Myc/E6/E7 axis and targeting this axis for the treatment of HPV-positive cervical cancer
|
Macharia, L.
|
|
|
211 |
S1 |
p.
|
artikel
|
| 455 |
251 (PB239): Time-dependant chromatin maturation 3D spheroids improves preclinical modeling of non-small cell lung cancer
|
Raynal, N.
|
|
|
211 |
S1 |
p.
|
artikel
|
| 456 |
315 (PB303): TRPML1 is a targetable vulnerability in AKT hyperactivated cancer by triggering ferroptosis defense
|
Zhang, H.L.
|
|
|
211 |
S1 |
p.
|
artikel
|
| 457 |
121 (PB109): TT125-802, a highly selective bromodomain inhibitor of CBP/p300, in patients with advanced solid tumors: an update on the phase I study
|
Boni, V.
|
|
|
211 |
S1 |
p.
|
artikel
|
| 458 |
387 (PB375): Tumor adaptation to PI3K inhibition and its stability increases as a function of time and is overcome by combined inhibiting Bcl2 family proteins
|
Mukherjee, R.
|
|
|
211 |
S1 |
p.
|
artikel
|
| 459 |
58 (PB046): Tumor-agnostic efficacy and safety of lirafugratinib, a highly selective FGFR2 inhibitor, in patients (pts) with advanced solid tumors with FGFR2 fusions or rearrangements (f/r): the ReFocus study
|
Hollebecque, A.
|
|
|
211 |
S1 |
p.
|
artikel
|
| 460 |
384 (PB372): TUSC2 gene therapy in KRASG12C mutant NSCLC overcomes acquired resistance to sotorasib
|
Meraz, I.
|
|
|
211 |
S1 |
p.
|
artikel
|
| 461 |
364 (PB352): TUSC2 Suppresses Tumorigenic Properties in Malignant Pleural Mesothelioma Cells
|
Goparaju, C.
|
|
|
211 |
S1 |
p.
|
artikel
|
| 462 |
72 (PB060): TYRA-300, an oral, FGFR3-selective inhibitor: Preliminary pharmacokinetic and pharmacodynamic analysis from SURF301, the multicenter open-label phase 1/2 study of TYRA-300 in advanced urothelial carcinoma and other solid tumors with activating FGFR3 alterations
|
Loriot, Y.
|
|
|
211 |
S1 |
p.
|
artikel
|
| 463 |
148 (PB136): UMF814A is a potent, selective and orally bioavailable STK17A inhibitor for MDS/AML
|
Bhalgat, A.
|
|
|
211 |
S1 |
p.
|
artikel
|
| 464 |
462 (PB450): Unbiased discovery of novel antibody therapies to stimulate macrophage-mediated destruction of B-cell lymphoma
|
Ribeiro, J.
|
|
|
211 |
S1 |
p.
|
artikel
|
| 465 |
455 (PB443): Uncovering a molecular mechanism of radiation-induced, T cell toxicity in cancer therapy
|
Sudaryo, V.
|
|
|
211 |
S1 |
p.
|
artikel
|
| 466 |
320 (PB308): Uncovering the Impact of Orphan G-Protein Coupled Receptor in ERα-Positive Breast Cancer
|
Kansiz, E.
|
|
|
211 |
S1 |
p.
|
artikel
|
| 467 |
446 (PB434): Understanding Chitinase-3-like-1’s role in chordoma immune evasion: implications for immunotherapy strategies
|
Michles, M.
|
|
|
211 |
S1 |
p.
|
artikel
|
| 468 |
422 (PB410): Understanding Mechanisms of Cancer Drug Sensitivity and Resistance Using Functional Genomic Approaches
|
Rosenberg, L.
|
|
|
211 |
S1 |
p.
|
artikel
|
| 469 |
215 (PB203): Unlocking the Potential IBI351 Enhances PD-1 Antibody Efficacy in KRASG12C Mutant Lung Cancer
|
Zhu, S.
|
|
|
211 |
S1 |
p.
|
artikel
|
| 470 |
14 (PB402): Xcellomics: powering rapid translation of HTS outputs to AI-driven drug discovery programmes
|
Aho, E.
|
|
|
211 |
S1 |
p.
|
artikel
|
| 471 |
440 (PB428): XON11, a novel multi-target treatment approach in pancreas cancer
|
Ciron, C.
|
|
|
211 |
S1 |
p.
|
artikel
|
| 472 |
421 (PB409): XPR1, key regulator of phosphate homeostasis is a potential drug target for ovarian and lung cancer
|
Pannier, P.
|
|
|
211 |
S1 |
p.
|
artikel
|
| 473 |
136 (PB124): Zongertinib (BI1810631), an irreversible HER2 TKI spares EGFR signaling and improves therapeutic response in preclinical models and patients with HER2-driven cancers
|
Neumueller, R.
|
|
|
211 |
S1 |
p.
|
artikel
|
| 474 |
177 (PB165): ZW251, a novel glypican-3-targeting antibody-drug conjugate bearing a topoisomerase I inhibitor payload demonstrates compelling preclinical activity in hepatocellular carcinoma models
|
Madera, L.
|
|
|
211 |
S1 |
p.
|
artikel
|
| 475 |
Peer Review Policy for the European Journal of Cancer (EJC)
|
|
|
|
211 |
S1 |
p.
|
artikel
|
| 476 |
Title Page
|
|
|
|
211 |
S1 |
p.
|
artikel
|
Tijdschrift beschrijving